'((Q!U25UQS,[
MZNU<%9Y0O\'/$2G]BI3^Y:3@U8K!"LN[C$@*B/RW%* UCG-H2/C>[/,3@7(GJ[,I8AU>/P%AZ< #=GUA;Y@59RC(:]&KT^MU:#8QAVVZMO39Q
MS2+B"-8;%JO?>$WZI^"-R;4%OQRJ
M+3E[">2:-= 1.3\D6U]Q?$:WEE:'JO143I@=MV5$":3C'])[A>&9%8:$\N68
M#T0X"G ZEH4] 4B0@03FB>"K38HDU$@DC/!3'E:HLEF#V#*'W0I?ZF
MNALXW;Y_-_3.N&YOP$L $$JO:LG) 2T-\S0$%F^57ZJ;(?P&)7DL2!83
ME=16KTKS9"$/L;0I[K!.$TGV0<VR31*^P, / . 9
M >&PO=V]R:W-H965T'M$&SK@]%'VCI;!&12(VD[0;8'[\C*)-1
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M?J>F)3I(R]!OSDI<(XA/07 ^K=WR@QW(_6[<;P9]68.^; 4]-;\+:YL_@;!?=WRFM?FL&?,
M@?W('Z0*^$3W,#ZB>[#%$9R&XXRZ!P>Z1]TXWM>]'>LWY"X(]W/WDHKKFY+[=&1; OWV&HB1OSS'
MG"FB,]@JM#!UL[)R1UK\VQN+)!?*B(TMRP-L+%!CH$EF[L;&U2H;0F&GDM.J
M:%@;C<.*NA9$/Y;0Q4,M'*9F3IDD*YHO#[%M3!QRAT!C9^3,^-(SGF_ +FP;9#"JK;DVAUOZM&ZU;JV#<;>^(UIP9K&@ZMID_VU'Z%#U#@3
M;[HY;PO)]8*W5.+Q49$^5>M"AMAS(3&OL=^YAA2PK2&.#\
M7&"74KV8!>HF=_(?4$L#!!0 ( **;5=C6)LRX $ (H# 9 >&PO
M=V]R:W-H965TQ;.MR3/=.L$5
M;@W85DIF_JY1Z&Z9W"4?!\_\6+MP0/*L84?"58V>I7"9I$(0""Q<8F-].^(A"!"(OX\_ F8PI
M W!J?[!_C[7[6@[,XJ,6OWGIZF7R-8$2*]8*]ZR['SC4,P]\A18VKM#UL?-Y
M D5KG98#V"N07/4[.P]]F HO0"@ R V@O2)HLH-R<\;?:D=-4
M#IFT-KS2G\PT96$Z+X7&I077
M*<7MKSE*LYTFDV2_\2 VC0\;K"Q:OL$5^F_MTI+%1I9:*-1.& T6U]-D-KE>
MY,$_.GP7N'4':PB1/!GS'(PO]31)@R"46/G P.GW@@N4,A"1C)\#9S)>&8"'
MZSW[IQ@[Q?+$'2Z,_"%JWTR3#PG4N.:=] ]F^QF'>"X#7V6DBU_8#KYI E7G
MO%$#F!0HH?L_WPUY. 0SW% -@"R?P7D R!FCO7*8E@WW/.RL&8+-G@36UC$
MW$0T12-TJ.+*6SH5A//EO?$(5_ .YMR)"KBNX4;(SF,-]]1#7XUSL$0+JX9;
MA),;]%Q(!X^X\QV7IP1TX<3M?T+#8V,Z1T2N8)X4AGM8-:B9]VJR5]3D<&>T
M;QS'H[<=G0=$,;'.A\;:CC!R-<,,[+\C=02P,$% @ HIM5Z,7;A_( @
MO@@ !D !X;"]W;W)K&ULK59K;]HP%/TK5CZM
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MA/@=0N0(T:D98D>(3\V0.((MW:]KM\*E5--^5XH5D0:-T8Q#J##*M#>+^>O%FD'/S
MSJ.]/K#U[EF;&>ITB4UG[L%E/[E*DJZ_W%2X!70976^#TK9(G1W0J"U2)VI
M6YK$C2;Q04WLRX,WY%H+>*G8DA; ]5J6(QK$>X<*=@0XBDB/(D:'$%MU)TW=
MR7_S0N8NF"-*)*>XH06T[X:V2'MN:(NTYP9_XT(N0(TJTVS
MO;4]9F=]T+D9=EK64VS.=2]]"U]W]CLJYXPK4L ,4P475WA467?+>J+%PK:#
M)Z&QN=AACA\8( T ]V<"6X*;F 3-)TO_#U!+ P04 " "BFU7'C#U-J$"
M "+!@ &0 'AL+W=OV^E"@2X/B)?&U[GW
MG'.OZY-T*]6C7B,:V'$F]#A8&U-=1I'.U\B)#F6%PKY92<6)L:$J(UTI)(4O
MXBQ*XG@8<4)%D*5^;ZZR5-:&48%S!;KFG*BG"3*Y'0>]X'GCGI9KXS:B+*U(
MB0LT#]5*6WVP!M?)4LI'%WPLQD'L
M!"'#W#@$8A\;G")C#LC*^+''#%I*5WBX?D:_];W;7I9$XU2RK[0PZW'P-H "
M5Z1FYEYN/^"^GX'#RR73_A>V3>[(,N:U-I+OBVW,J6B>9+>?PT%!DKQ0D.P+
M$J^[(?(JKXDA6:KD%I3+MFANX5OUU58<%>Y0%D;9M]36F>R3- @C> -3R3DU
M=MQ& Q&%C86AHD214]1P>HV&4*;A,^Y,3=@9G 5,*.,V=GJ-#)6BT.,\CWO
MI.%-7N!]!S-+L-9P(PHL?J^/; ]M(\ES(Y.D$W"!50C]^!R2..G#P^(:3D_.
M.G#[[8#Z'O?B!=PI8=3^]P4E<$>VNJ8&OLV0+U%]/]9U)YB[89>Z(CF. WN%
M-*H-!MGK5[UA_+Y#ZD4K]:)3ZIW4^N#[*'2R%J;QBG:W==JKQF!^I3]GF>8 @, -\) 9 >&PO=V]R:W-H965T,JS0HRL5,KRS+9%G&).Q#$KL5 S4\9S(E67
MSVQ169[3E.8.>$%E8X-&-C'@[97&:TP#$',<]SPE<7F+'ER'*MYX$)
MG:52#]CAL"0SO$%Y5XZYZMD-2T)S+ 1E!7"(E9IHE4&K]K3JM94@/7V\_L7XQVI>6!"+QD
MV3U-9#JR!A8D."7S3$[8\BO6>DXT7\PR89ZPK&*#4POBN9 LK\$J@YP6U9L\
MU3ZL ;Q@"\"K =YK ;T:T-L N/X6@%\#?.-,)<7X$!%)PB%G2^ Z6K'IAC'3
MH)5\6NAMOY%FJ?"9*$N/(4F57
M(%^@%7[\X ;.IXZ-/&DTG^RF^=[4,4S@?*%F9@@1%3&;%Q(F1*KY,?(8B];=
MK59RO36USK'3.]WPY'5A46?>;W0E:%P)WNG*!/6)UT2H$L9SV/^%A!^T6=.]
MG .Q!SYS%PM!)A_I3H=F]'F]G)N#FW[;WAU];DF
M?$8+ 1E.%=0Y[JMOGU?7B:HC66D.V &PO=V]R:W-H965T
MT96VE431M$@S$9?OLMJ>-
M11)GMM/"O]]Q$D+;! /]TL:.SWN>U_'E#-=,H80)&G-,GDR(J5RL]L6\YB
M2*D\Y3ED^&;!14H5-L72EKD .B^#TL3V'">R4\HR:SPL^V[$>,@+E; ,;@21
M19I2\7P."5^/+-=ZZ;AERUCI#GL\S.D2[D ]Y#<"6W:C,FC.>R/*7K.NQ
MCD5FA50\K8.1(&59]4^?ZHG8"'"#-P*\.L#[:(!?!_BET8JLM'5!%1T/!5\3
MH4>CFGXHYZ:,1C"T2.RZHJH0
M3#%L\$7532X9G;*DZCR\ $59(H]P[,/=!3D\."('A&7D/N:%I-E<#FV%C#J3
M/:MYSBL>[PV>.\A/B>\<$\_Q_([PB3G\ F88[I;AWG:XC3/33(_73(]7Z@5O
MZ%W/%)^"()6B?TQ4+'BQC DF@E2_J9-UL9Y7VE&IK??3:NP-<.!JTX\QO][$
M9S*G,QA9N$LEB!58XZ]?W,CY9G#G-^Y\HSOD#KJXJZAP@]MUG6@'W"B])WC0
M@ ?O@8==X$$+/(R"'6ZC\I[<8<,=OL<==7&'+>X@*
M)B0I3X"[HHWIMK32*\QTC,:N00IS_"(4H#:JLM"KV7A
MQ T'.Q:,2?:TT&\L](T6;K1DILB*)@7H@[GZ+,GKP=QEJ]_^,EYK:Q@3[VEK
MT-@:&&U-"B&T+=[<0Q_R-6@?54[8W_$U:)W#KN/WFD%;O*[S>G,ZYK7$L^4)
M+J3TL\RU[A:TUSI?ZU%;U .__P;UQGWOFF^T[7O^N+G1GSM1W?85UEXWYI2?
M73CV1C6C2\DK*I8LDSBW"Y1W3GLX<:*JSJJ&XGE9X$RYPG*I?(RQH@6A!^#[
M!<)CVX":WB45B!]MINW\_VPE9@%*8]M+XXYR39(BK8
MY1F3(R=5JKAT71FEF!/9X04RO;/F(B=*3T7BRD(@B2TISUS?\P9N3BASPJ%=
M6XAPR$N5488+ ;+, GY0W,K6&$R2%>>/9G(=CQS/&,(,(V44B'YL<(I9
M9H2TC:=:TVE>:8CM\;/Z5YM=9UD1B5.>/=!8I2/GW($8UZ3,U"W??L,Z3]_H
M13R3]A>V-=9S("JEXGE-U@YRRJHGV=5U:!%\_QV"7Q/\SQ*"FA#8H)4S&VM&
M% F'@F]!&+16,P-;&\O6:2@SI[A40N]2S5/A=ZX0+N +S'"EX'B&BM!,PAWN
M5$FR$[TQ(2P"OH9QCH)&!.9()&4)$!;#E!14D0Q^WF"^0O%+PZ^>2EKH8U8P
MYX3!6 C"$K0++=1T< 65PE_)2:GDY=)6.:(RZ41UG4L7QWXD3
MP UG*I5PQ6*,]_"GA_D7!_BN+FU37_^YOA/_H. 2BPX$WBGXGA_ _7(&QTT%S_('5[;VC:T[]%![LGQUC&&]0Z&\7KIE"@5+!+5&X[Q0JU6YE
MUW2*3>AUO.!\Z&[:H3Z$O3#=:TSW#IINW%WM=#.3>PU6"H/6BWNOO+U%='O[
M??4;7_V#ON:<)5_N4.3PF;*> E&PX%1_&.8_KUOCOAS]SQ7Z0]B+0(,FT. ?
M NVS-WA3Q.#LXI6WPYC*F-OJ8+K/)+:Q2XAXR535S)K5YNX8VY;I_H57%\\-
M$0EE$C)<:ZK7.=.U$54SKR:*%[8?KKC2W=4.4WW_H3 O;_FNB?6$_."YD8-
M_P!02P,$% @ HIM5[X/V?$( P B0H !D !X;"]W;W)K&ULO99M3]LP$,>_BI6A"20@:=)'UD:"=FB38" ZMA?37KCI
MY4$D=K"=%K[]SDD:A39$K$*\:>WX[OS_G>W3C==,@00)&G)&9R8H1*I6>F
M*;T0$BI/>0H,5WPN$JIP*@)3I@+H,G=*8M.VK+Z9T(@9[CC_=BO<,<]4'#&X
M%41F24+%\P7$?#TQ.L;FPUT4A$I_,-UQ2@.8@[I/;P7.S"K*,DJ R8@S(L"?
M&.>=L^E(V^<&OR)8R]J8:)(%YP]Z\GTY,2PM"&+PE(Y \6\%4XAC'0AE/)8Q
MC6I+[5@?;Z)?YNS(LJ 2ICS^'2U5.#&&!EF"3[-8W?'U-RAY>CJ>QV.9_Y)U
M:6L9Q,NDXDGIC J2B!7_]*G,0\VATWW%P2X=[+R--Q/0ISI7 U0C]E/N#*R C1<",H"P)-3$NWF>(^660R$^X7/':3TN5@]G(&B42R/T.Y^/B.'!T?D@$2,
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M)Y(/0^P506@#7/E( P
M>PT !D !X;"]W;W)K&ULK5==;]HP%/TK5E9-
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M4OH*6L 2KR-^3[:W4.1C2;TYB5CV%VUSK.,J:+YFG,0%6:R.8!<%\;02K(&2IJWGN6>$\S/%X2,D648D6:K*1
M53]CBWJ%B?3)E%/Q-10\/OY*."!=0Q_1/6P@6<->:_:")O@WH6A*UG0.Z-P#
MCL.(70C,X]1#YV<7Z R%"7H(R)KA9,&&*A=SDLKJO(A_G<,"0
MGRQ@T<#WVOEN"U\5M2@+8NP*) VYV1Y[MUFL5?:OU
MNA3SNA3S.Q([6!FG7!GG9.LY-2OT=;?BO#K&W=N4\F+5,8:M5]SI-X'Z1[:W
M?IE&PO=V]R:W-H965T'J@\F#,3=Q$YM!ZC4CZ_MA)"P;%I6O( O,V?.FV+<(($BQ:+ 6J;E:,)UBJ+5_;(N6 E\8IB6W/<7IV
M@@FU M^<37G@LTS&A,*4(Y$E">:_1Q"S[=!RK?W!C*PCJ0_LP$_Q&N8@OZ13
MKG9VB;(D"5!!&$4<5D/KUKT9NXYV,!9?"6Q%98VTE 5C#WKS<3FT',T(8@BE
MAL#J;P-CB&.-I'C\*D"M,J9VK*[WZ.^->"5F@06,6?R-+&4TM 866L(*9[&<
ML>T'* 1U-5[(8F%^T;:P=2P49D*RI'!6#!)"\W^\*Q)1<5 XIQV\PL$[=N@\
MX= N'-I&:,[,R+K#$@<^9UO$M;5"TPN3&^.MU!"JRSB77-T2Y2>#>R8!N2YZ
M@^9D3RP8#+*F7A/,+E&$T9E)- [NH1EW=]6JDIIWE[:R&L$G$/:
M0FWG"GF.US[!9_S_[EX#G7:9Z;;!ZSR!-X,-T S0"&@8J99ISE4CEN[M&Y'B
M$(:6:EX!? -6\/*%VW/>GA)Z(;":[$XIN],H^S[3&A%;H0G^R?CAT3JE.H?J
M&BC] MH$KF]OJE(>6SBE18U?M^37?699T)_#D_Z)0F.Y&F.<6ZX+@=72T2O3
MT6M,Q^.6OD)3X/I,O=5/2<_QW':U)"VW8%P*K"1^4P@>7Z[W!/WNOR:+&[[KD=_WLPIS3?8U1SBW8
MACUCXIWVJS2ISEANS)*J-2OS80ED*E3_NDM3\LI
M[M;,+D?G(SW=F1'E )./AA/,UX0*%,-*03JMOGJB>#YMY1O)4C.P+)A4]3?+
M2$VHP+6!NE\Q-;04&QV@G'F#OU!+ P04 " "BFU7E6#V:D0# #*%
M#0 'AL+W-T>6QEE7G%Z-Z=4>\N<
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M.,W CF*S.=RU+ ( M9:Y::2,S*0@E8[Q_9EO8RV]BQ:K]$
MTS2&ZJ:5L1W0WU2SVINRER_2]0KV*/7GA9F.J/I0V/16T8PMJ_XR:PQ@ZAU<
MG10%7WWB;"9R:B=_<,+1@*QYWEPJ]F2R0:E,38 JWWND2K/I9N27(L4]7>IU
M.2TSW'/W#7K^M^L\HX(JPC=-F]H_YE5^L>.H]UJ6JV^57<-.C_4[^]A-7KT%
MD_'QFXR2X_=8GYR.W63_+9A\"]O=>[5O]KTF@_HDM''\V7B'[ZP#;TWT5@LT4KT1LIOA:
M ^)>-V DB7NWL3S P'8!JQW([\X#->7F1!'L*N8->X)Q)$DP!&K17:-QC*Q.
M#!_W_F!/210EB1L!S.T@BC $GD8, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TX
MI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606
MIW.D5XA-/E
M_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU
M@LD/['X 4$L#!!0 ( **;5=^XA;6O0, 0< / >&PO=V]R:V)O
M;VLN>&ULQ9G?<#;*='U-WIA=?[S+3)IDZD]<;&=:Q)D+R
M2"))^]=W@>,BVK!S+X@G@Y#%AV#WT\+[9V,?=\8\LI=2:;=.#MX?+V8SEQ^@
M%.YW-^-=6MGX8[QD'MI
M-#;6#?<2GMWK\7J7/4DG=U))_VV=--L*$E9*+4OY'8IU,D^8.YCGOXV5WXWV
M0FUS:Y1:)VE[X!ZLE_DOS=L:\D[L7-/BQ>ZK0)!ULIKC@'MIG6]Z-.,+9'P"
M[-SN5=Y\DLJ#W0@/?UE3':5^J(?!JY@%E]',0_?;3N*%_3_3:/9[F&Y%4)
MVK?S:$'5@-H=Y-$E3(L2UDG7A7W4!?M3>YPD=J7;H;!O?:5XZJNBO6J/N,$<
MV@N)!^Q5T8"/!WEI= ':0<%PRQDE"^0HV!]""9T#"R S C*;$/*?+(#D!"2?
M!');X^!? \@% ;F8$+(WDTL"C@MYC2FP$
M0\5)Q\R>W5IP^)^?,] 9P7@6@3%#QD]28SA+H0:RY#G!>!Z!D=>,0EIV+U0%
M[ L(5]DZM'V8RN=4+I]'P%P@YM:;_/%D)]K'L\0A'?8.,4GEC.R8QCV[NI
ME%'2D942PGW,2>+X9W!%-3#I+R3Q2AE!C'#FC"CO)/%\,X@
MYC)\G4)YAT_JG56(27F'3U'-L'<;\$(J%T8ZI[S#IZQK>B'$R9=H,;PSB!F&
M$*<$Q&,(:*C\ZK^1I"S$8UCH[<5&_7R&F)2%> P+O8EYPKZ(L"SCE(5X# N]
MKHFZ"+^#%U\)%2X].&4A'L-"_V'6#^6-/X#M5B(A)F4A'L-"O37&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V4V.@D 0AN&K& Y@6U7X
M-U%7LW$[\0)$6S&"$+HGH[PS,H8VP_GPK;T=1&&3>O/MS/[IJN+>%MV!]<6VU-Q\$Y'HXGK7F=D
MJ\7KS,'FVOK_3&SV^^/6?S;;[]J?XQ^#W4_3G4+I?0J"WHMY*H+>BWDJ@M_9>M@GT5M1;"?16U%L)]%;4
M6PGT5M1;"?16U%L)]%;46PGT5M1;"?0VU-L(]#;4VPCT-M3;"/2VWL<2 KT-
M]38"O0WU-@*]#?4V KT-]38"O0WU-@*]#?4V KUSU#LGT#M'O?-WZAWBM?+A
MV?-8X_W?276\7>N?M[\O'YN]AW#'V<$OC=4O4$L#!!0 ( **;5>(C*DW
MI0$ "\9 3 6T-O;G1E;G1?5'EP97-=+GAM;,V9S6Z#,!"$7P5QC8)C
M.TU_E.32]MKFT!=P80DH@"W;29.WKR$_4JL4-4JES@4+O#LS>*7O -.WG2$7
M;>NJ<;.X\-X\,.;2@FKE$FVH"3NYMK7RX=8NF5'I2BV)B=%HPE+=>&K\T+<:
M\7SZ1+E:5SYZWH;'KM3-++94N3AZW!>V7K-8&5.5J?)AGVV:[)O+\."0A,ZN
MQA6E<8-0$+.S#NW.SP:'OM<-65MF%"V4]2^J#E5L6S'G=Q6YI%_B3$:=YV5*
MF4[7=6A)G+&D,E<0^;I*]J*#?F3ICV5WZU?R?39Q@J%U8;%R9FZ7*[XTC:
M[J$)0F1]V?^*)\<@??7[43OMC+)?>H?C_=!VUM5W_]";]=DUJ5S=&?=?])
MYI]02P$"% ,4 " "BFU7!T%-8H$ "Q $ @ $
M 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( **;5?\/'L@[P "L"
M 1 " :\ !D;V-097)PC$ 8 )PG 3 " &UL4$L! A0#% @ HIM5ZZFB]C.!0 UQX !@
M ("!#@@ 'AL+W=O&PO=V]R:W-H965T&UL4$L!
M A0#% @ HIM5RGT(>6-!0 4AD !@ ("!*!@ 'AL
M+W=O*0K1$F @
M +$^ 8 " @>L= !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ HIM5[(>
M,J.R!@ -QP !@ ("!,"D 'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#% @ HIM5YX_4D3Y P 9@@ !D
M ("![#< 'AL+W=O&PO=V]R
M:W-H965T&UL
M4$L! A0#% @ HIM5]!YCL=S P ; D !D ("!CD0
M 'AL+W=O&PO=V]R:W-H965TEW4H)] ( . & 9
M " @8A, !X;"]W;W)K&UL4$L! A0#% @
M HIM5Y83X@$; P )@< !D ("!LT\ 'AL+W=O&PO=V]R:W-H965T"NU$\: ( &(% 9 " @1-6 !X;"]W
M;W)K&UL4$L! A0#% @ HIM5^K(E@ / P
MQ0< !D ("!LE@ 'AL+W=O!@ &0 @('X
M6P >&PO=V]R:W-H965TY> !X;"]W;W)K&UL4$L! A0#% @ HIM5_LCH%R2 @ _@4 !D
M ("!'V, 'AL+W=O&PO=V]R:W-H
M965T&UL4$L!
M A0#% @ HIM5_TR6&^/ @ I04 !D ("!?FL 'AL
M+W=O&PO=V]R:W-H965T+=_'#^ ( )@, 9 "
M@4AP !X;"]W;W)K&UL4$L! A0#% @ HIM
M5] 8D!SX!P I% !D ("!=W, 'AL+W=O&EF3Q # !7"P &0
M @(&F>P >&PO=V]R:W-H965TFD)E:Q 0 +,4 9 " @>U^ !X;"]W;W)K
M&UL4$L! A0#% @ HIM5[;)-$K[ P \ X
M !D ("!Z(, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ HIM5Z,7;A_( @ O@@ !D
M ("!MXP 'AL+W=O&PO=V]R:W-H965T
M]GF>8 @, -\) 9
M " @8Z2 !X;"]W;W)K&UL4$L! A0#
M% @ HIM5S241# J P +PL !D ("!QY4 'AL+W=O
M&PO=V]R:W-H965T^#]GQ" , (D* 9 " @1J<
M !X;"]W;W)K&UL4$L! A0#% @ HIM5T#Y
MM>E( P >PT !D ("!69\ 'AL+W=O&PO=V]R:W-H965T58/9J1 , ,H4 - " 0.F !X;"]S='EL97,N
M>&UL4$L! A0#% @ HIM5Y>*NQS $P( L ( !
M(C*DWI0$ "\9 3
M " 1"P !;0V]N=&5N=%]4>7!E&UL4$L%!@ Q #$
*3@T .:Q $!
end
XML
52
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
53
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
54
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.23.3
html
118
199
1
true
31
0
false
6
false
false
R1.htm
000 - Document - Document And Entity Information
Sheet
http://www.psychemedics.com/20230930/role/statement-document-and-entity-information
Document And Entity Information
Cover
1
false
false
R2.htm
001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)
Sheet
http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Statements
2
false
false
R3.htm
002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Sheet
http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Statements
3
false
false
R4.htm
003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)
Sheet
http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited
Condensed Consolidated Statements of Operations (Unaudited)
Statements
4
false
false
R5.htm
004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)
Sheet
http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited
Condensed Consolidated Statements of Shareholders' Equity (Unaudited)
Statements
5
false
false
R6.htm
005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)
Sheet
http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)
Statements
6
false
false
R7.htm
006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)
Sheet
http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited
Condensed Consolidated Statements of Cash Flows (Unaudited)
Statements
7
false
false
R8.htm
007 - Disclosure - Note 1 - Basis of Presentation
Sheet
http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation
Note 1 - Basis of Presentation
Notes
8
false
false
R9.htm
008 - Disclosure - Note 2 - Financial Information
Sheet
http://www.psychemedics.com/20230930/role/statement-note-2-financial-information
Note 2 - Financial Information
Notes
9
false
false
R10.htm
009 - Disclosure - Note 3 - Fair Value Measurements
Sheet
http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements
Note 3 - Fair Value Measurements
Notes
10
false
false
R11.htm
010 - Disclosure - Note 4 - Stock-based Compensation
Sheet
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation
Note 4 - Stock-based Compensation
Notes
11
false
false
R12.htm
011 - Disclosure - Note 5 - Income Taxes
Sheet
http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes
Note 5 - Income Taxes
Notes
12
false
false
R13.htm
012 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share
Sheet
http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share
Note 6 - Basic and Diluted Net Loss Per Share
Notes
13
false
false
R14.htm
013 - Disclosure - Note 7 - Commitments and Contingencies
Sheet
http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies
Note 7 - Commitments and Contingencies
Notes
14
false
false
R15.htm
014 - Disclosure - Note 8 - Operating Leases
Sheet
http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-
Note 8 - Operating Leases
Notes
15
false
false
R16.htm
015 - Disclosure - Note 9 - Debt
Sheet
http://www.psychemedics.com/20230930/role/statement-note-9-debt
Note 9 - Debt
Notes
16
false
false
R17.htm
016 - Disclosure - Note 10 - Revenue
Sheet
http://www.psychemedics.com/20230930/role/statement-note-10-revenue
Note 10 - Revenue
Notes
17
false
false
R18.htm
017 - Disclosure - Note 11 - Significant Customers
Sheet
http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers
Note 11 - Significant Customers
Notes
18
false
false
R19.htm
018 - Disclosure - Significant Accounting Policies (Policies)
Sheet
http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies
Significant Accounting Policies (Policies)
Policies
19
false
false
R20.htm
019 - Disclosure - Note 3 - Fair Value Measurements (Tables)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables
Note 3 - Fair Value Measurements (Tables)
Tables
http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements
20
false
false
R21.htm
020 - Disclosure - Note 4 - Stock-based Compensation (Tables)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables
Note 4 - Stock-based Compensation (Tables)
Tables
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation
21
false
false
R22.htm
021 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share (Tables)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables
Note 6 - Basic and Diluted Net Loss Per Share (Tables)
Tables
http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share
22
false
false
R23.htm
022 - Disclosure - Note 8 - Operating Leases (Tables)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables
Note 8 - Operating Leases (Tables)
Tables
http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-
23
false
false
R24.htm
023 - Disclosure - Note 9 - Debt (Tables)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables
Note 9 - Debt (Tables)
Tables
http://www.psychemedics.com/20230930/role/statement-note-9-debt
24
false
false
R25.htm
024 - Disclosure - Note 10 - Revenue (Tables)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables
Note 10 - Revenue (Tables)
Tables
http://www.psychemedics.com/20230930/role/statement-note-10-revenue
25
false
false
R26.htm
025 - Disclosure - Note 2 - Financial Information (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-2-financial-information-details-textual
Note 2 - Financial Information (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-2-financial-information
26
false
false
R27.htm
026 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details
Note 3 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)
Details
27
false
false
R28.htm
027 - Disclosure - Note 4 - Stock-based Compensation (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual
Note 4 - Stock-based Compensation (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables
28
false
false
R29.htm
028 - Disclosure - Note 4 - Stock-based Compensation - Compensation Cost (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details
Note 4 - Stock-based Compensation - Compensation Cost (Details)
Details
29
false
false
R30.htm
029 - Disclosure - Note 4 - Stock-based Compensation - Stock Option Activity (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details
Note 4 - Stock-based Compensation - Stock Option Activity (Details)
Details
30
false
false
R31.htm
030 - Disclosure - Note 4 - Stock-based Compensation - Nonvested Award Activity (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details
Note 4 - Stock-based Compensation - Nonvested Award Activity (Details)
Details
31
false
false
R32.htm
031 - Disclosure - Note 5 - Income Taxes (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes-details-textual
Note 5 - Income Taxes (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes
32
false
false
R33.htm
032 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-details-textual
Note 6 - Basic and Diluted Net Loss Per Share (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables
33
false
false
R34.htm
033 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share - Basic and Diluted Weighted Average Common Shares Outstanding (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details
Note 6 - Basic and Diluted Net Loss Per Share - Basic and Diluted Weighted Average Common Shares Outstanding (Details)
Details
34
false
false
R35.htm
034 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual
Note 7 - Commitments and Contingencies (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies
35
false
false
R36.htm
035 - Disclosure - Note 8 - Operating Leases (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual
Note 8 - Operating Leases (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables
36
false
false
R37.htm
036 - Disclosure - Note 8 - Operating Leases - Maturities of Lease Liabilities (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details
Note 8 - Operating Leases - Maturities of Lease Liabilities (Details)
Details
37
false
false
R38.htm
037 - Disclosure - Note 9 - Debt (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual
Note 9 - Debt (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables
38
false
false
R39.htm
038 - Disclosure - Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details
Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)
Details
39
false
false
R40.htm
039 - Disclosure - Note 10 - Revenue - Revenue by Major Source (Details)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details
Note 10 - Revenue - Revenue by Major Source (Details)
Details
40
false
false
R41.htm
040 - Disclosure - Note 11 - Significant Customers (Details Textual)
Sheet
http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual
Note 11 - Significant Customers (Details Textual)
Details
http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers
41
false
false
All Reports
Book
All Reports
pmd-20230930.xsd
pmd-20230930_cal.xml
pmd-20230930_def.xml
pmd-20230930_lab.xml
pmd-20230930_pre.xml
pmd20230930_10q.htm
http://fasb.org/us-gaap/2023
http://xbrl.sec.gov/dei/2023
true
true
JSON
57
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"pmd20230930_10q.htm": {
"nsprefix": "pmd",
"nsuri": "http://www.psychemedics.com/20230930",
"dts": {
"schema": {
"local": [
"pmd-20230930.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
"https://xbrl.sec.gov/country/2023/country-2023.xsd",
"https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
"https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
"https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
"https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
"https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
"https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
"https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
]
},
"calculationLink": {
"local": [
"pmd-20230930_cal.xml"
]
},
"definitionLink": {
"local": [
"pmd-20230930_def.xml"
]
},
"labelLink": {
"local": [
"pmd-20230930_lab.xml"
]
},
"presentationLink": {
"local": [
"pmd-20230930_pre.xml"
]
},
"inline": {
"local": [
"pmd20230930_10q.htm"
]
}
},
"keyStandard": 185,
"keyCustom": 14,
"axisStandard": 16,
"axisCustom": 0,
"memberStandard": 17,
"memberCustom": 13,
"hidden": {
"total": 159,
"http://fasb.org/us-gaap/2023": 150,
"http://xbrl.sec.gov/dei/2023": 6,
"http://www.psychemedics.com/20230930": 3
},
"contextCount": 118,
"entityCount": 1,
"segmentCount": 31,
"elementCount": 304,
"unitCount": 6,
"baseTaxonomies": {
"http://fasb.org/us-gaap/2023": 521,
"http://xbrl.sec.gov/dei/2023": 29
},
"report": {
"R1": {
"role": "http://www.psychemedics.com/20230930/role/statement-document-and-entity-information",
"longName": "000 - Document - Document And Entity Information",
"shortName": "Document And Entity Information",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R2": {
"role": "http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)",
"shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "2",
"firstAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-4",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-4",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R3": {
"role": "http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
"shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "parenthetical",
"menuCat": "Statements",
"order": "3",
"firstAnchor": null,
"uniqueAnchor": null
},
"R4": {
"role": "http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
"shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "4",
"firstAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:CostOfGoodsAndServicesSold",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"unique": true
}
},
"R5": {
"role": "http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
"longName": "004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
"shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "5",
"firstAnchor": {
"contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
"name": "us-gaap:SharesOutstanding",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
"name": "us-gaap:SharesOutstanding",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R6": {
"role": "http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals",
"longName": "005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)",
"shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "parenthetical",
"menuCat": "Statements",
"order": "6",
"firstAnchor": null,
"uniqueAnchor": null
},
"R7": {
"role": "http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
"shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "7",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "pmd:DepreciationAndAmortizationExcludingRouAssetAmortization",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "pmd:DepreciationAndAmortizationExcludingRouAssetAmortization",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R8": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation",
"longName": "007 - Disclosure - Note 1 - Basis of Presentation",
"shortName": "Note 1 - Basis of Presentation",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "8",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R9": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-2-financial-information",
"longName": "008 - Disclosure - Note 2 - Financial Information",
"shortName": "Note 2 - Financial Information",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "9",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R10": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements",
"longName": "009 - Disclosure - Note 3 - Fair Value Measurements",
"shortName": "Note 3 - Fair Value Measurements",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "10",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R11": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"longName": "010 - Disclosure - Note 4 - Stock-based Compensation",
"shortName": "Note 4 - Stock-based Compensation",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "11",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R12": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes",
"longName": "011 - Disclosure - Note 5 - Income Taxes",
"shortName": "Note 5 - Income Taxes",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "12",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R13": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share",
"longName": "012 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share",
"shortName": "Note 6 - Basic and Diluted Net Loss Per Share",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "13",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:EarningsPerShareTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:EarningsPerShareTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R14": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"longName": "013 - Disclosure - Note 7 - Commitments and Contingencies",
"shortName": "Note 7 - Commitments and Contingencies",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "14",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R15": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-",
"longName": "014 - Disclosure - Note 8 - Operating Leases",
"shortName": "Note 8 - Operating Leases",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "15",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R16": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"longName": "015 - Disclosure - Note 9 - Debt",
"shortName": "Note 9 - Debt",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "16",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:DebtDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:DebtDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R17": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-10-revenue",
"longName": "016 - Disclosure - Note 10 - Revenue",
"shortName": "Note 10 - Revenue",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "17",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R18": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"longName": "017 - Disclosure - Note 11 - Significant Customers",
"shortName": "Note 11 - Significant Customers",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "18",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R19": {
"role": "http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies",
"longName": "018 - Disclosure - Significant Accounting Policies (Policies)",
"shortName": "Significant Accounting Policies (Policies)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "policies",
"menuCat": "Policies",
"order": "19",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "pmd:LiquidityAndManagementsPlanPolicyTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "pmd:LiquidityAndManagementsPlanPolicyTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R20": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables",
"longName": "019 - Disclosure - Note 3 - Fair Value Measurements (Tables)",
"shortName": "Note 3 - Fair Value Measurements (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "20",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R21": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables",
"longName": "020 - Disclosure - Note 4 - Stock-based Compensation (Tables)",
"shortName": "Note 4 - Stock-based Compensation (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "21",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R22": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables",
"longName": "021 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share (Tables)",
"shortName": "Note 6 - Basic and Diluted Net Loss Per Share (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "22",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R23": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables",
"longName": "022 - Disclosure - Note 8 - Operating Leases (Tables)",
"shortName": "Note 8 - Operating Leases (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "23",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:LesseeOperatingLeasesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:LesseeOperatingLeasesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R24": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables",
"longName": "023 - Disclosure - Note 9 - Debt (Tables)",
"shortName": "Note 9 - Debt (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "24",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R25": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables",
"longName": "024 - Disclosure - Note 10 - Revenue (Tables)",
"shortName": "Note 10 - Revenue (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "25",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:RevenueFromContractWithCustomerTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:RevenueFromContractWithCustomerTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R26": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-2-financial-information-details-textual",
"longName": "025 - Disclosure - Note 2 - Financial Information (Details Textual)",
"shortName": "Note 2 - Financial Information (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "26",
"firstAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:Cash",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-5",
"ancestors": [
"p",
"pmd:LiquidityAndManagementsPlanPolicyTextBlock",
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:Cash",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-5",
"ancestors": [
"p",
"pmd:LiquidityAndManagementsPlanPolicyTextBlock",
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R27": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details",
"longName": "026 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
"shortName": "Note 3 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "27",
"firstAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R28": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"longName": "027 - Disclosure - Note 4 - Stock-based Compensation (Details Textual)",
"shortName": "Note 4 - Stock-based Compensation (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "28",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-4",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"unique": true
}
},
"R29": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details",
"longName": "028 - Disclosure - Note 4 - Stock-based Compensation - Compensation Cost (Details)",
"shortName": "Note 4 - Stock-based Compensation - Compensation Cost (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "29",
"firstAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R30": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details",
"longName": "029 - Disclosure - Note 4 - Stock-based Compensation - Stock Option Activity (Details)",
"shortName": "Note 4 - Stock-based Compensation - Stock Option Activity (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "30",
"firstAnchor": {
"contextRef": "i_2022-12-31",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30",
"name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"unique": true
}
},
"R31": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details",
"longName": "030 - Disclosure - Note 4 - Stock-based Compensation - Nonvested Award Activity (Details)",
"shortName": "Note 4 - Stock-based Compensation - Nonvested Award Activity (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "31",
"firstAnchor": {
"contextRef": "i_2022-12-31_AwardTypeAxis-StockUnitAwardMember",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2022-12-31_AwardTypeAxis-StockUnitAwardMember",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R32": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes-details-textual",
"longName": "031 - Disclosure - Note 5 - Income Taxes (Details Textual)",
"shortName": "Note 5 - Income Taxes (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "32",
"firstAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:DeferredTaxAssetsValuationAllowance",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"p",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:DeferredTaxAssetsValuationAllowance",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"p",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R33": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-details-textual",
"longName": "032 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share (Details Textual)",
"shortName": "Note 6 - Basic and Diluted Net Loss Per Share (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "33",
"firstAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R34": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details",
"longName": "033 - Disclosure - Note 6 - Basic and Diluted Net Loss Per Share - Basic and Diluted Weighted Average Common Shares Outstanding (Details)",
"shortName": "Note 6 - Basic and Diluted Net Loss Per Share - Basic and Diluted Weighted Average Common Shares Outstanding (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "34",
"firstAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
"unitRef": "Share",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"us-gaap:EarningsPerShareTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R35": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual",
"longName": "034 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)",
"shortName": "Note 7 - Commitments and Contingencies (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "35",
"firstAnchor": {
"contextRef": "i_2023-09-30_LitigationCaseAxis-CaliforniaLawsuitMember",
"name": "us-gaap:LossContingencyAccrualAtCarryingValue",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-5",
"ancestors": [
"p",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2023-09-30_LitigationCaseAxis-CaliforniaLawsuitMember",
"name": "us-gaap:LossContingencyAccrualAtCarryingValue",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-5",
"ancestors": [
"p",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R36": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual",
"longName": "035 - Disclosure - Note 8 - Operating Leases (Details Textual)",
"shortName": "Note 8 - Operating Leases (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "36",
"firstAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:OperatingLeaseRightOfUseAsset",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:OperatingLeaseExpense",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"p",
"us-gaap:LesseeOperatingLeasesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"unique": true
}
},
"R37": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details",
"longName": "036 - Disclosure - Note 8 - Operating Leases - Maturities of Lease Liabilities (Details)",
"shortName": "Note 8 - Operating Leases - Maturities of Lease Liabilities (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "37",
"firstAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"us-gaap:LesseeOperatingLeasesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"us-gaap:LesseeOperatingLeasesTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
},
"R38": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual",
"longName": "037 - Disclosure - Note 9 - Debt (Details Textual)",
"shortName": "Note 9 - Debt (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "38",
"firstAnchor": {
"contextRef": "i_2023-09-30_CreditFacilityAxis-LineOfCreditMember_DebtInstrumentAxis-EquipmentLoanArrangementMember_LineOfCreditFacilityAxis-BancOfAmericaLeasingAndCapitalMember",
"name": "us-gaap:DebtWeightedAverageInterestRate",
"unitRef": "Pure",
"xsiNil": "false",
"lang": null,
"decimals": "3",
"ancestors": [
"p",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "d_2023-07-01_2023-09-30_CreditFacilityAxis-LineOfCreditMember_DebtInstrumentAxis-EquipmentLoanArrangementMember_LineOfCreditFacilityAxis-BancOfAmericaLeasingAndCapitalMember",
"name": "us-gaap:InterestExpense",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"p",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"unique": true
}
},
"R39": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"longName": "038 - Disclosure - Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)",
"shortName": "Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "39",
"firstAnchor": {
"contextRef": "i_2023-09-30",
"name": "us-gaap:LongTermDebtCurrent",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "i_2023-09-30_LongtermDebtTypeAxis-EquipmentLoanArrangementMember",
"name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"unique": true
}
},
"R40": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details",
"longName": "039 - Disclosure - Note 10 - Revenue - Revenue by Major Source (Details)",
"shortName": "Note 10 - Revenue - Revenue by Major Source (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "40",
"firstAnchor": {
"contextRef": "d_2023-07-01_2023-09-30",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "d_2023-07-01_2023-09-30_ProductOrServiceAxis-TestingMember",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"unitRef": "USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:DisaggregationOfRevenueTableTextBlock",
"us-gaap:RevenueFromContractWithCustomerTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"unique": true
}
},
"R41": {
"role": "http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual",
"longName": "040 - Disclosure - Note 11 - Significant Customers (Details Textual)",
"shortName": "Note 11 - Significant Customers (Details Textual)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "41",
"firstAnchor": {
"contextRef": "d_2023-01-01_2023-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember",
"name": "pmd:NumberOfMajorCustomers",
"unitRef": "Pure",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"p",
"us-gaap:ConcentrationRiskDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "d_2023-01-01_2023-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember",
"name": "pmd:NumberOfMajorCustomers",
"unitRef": "Pure",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"p",
"us-gaap:ConcentrationRiskDisclosureTextBlock",
"body",
"html"
],
"reportCount": 1,
"baseRef": "pmd20230930_10q.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
}
}
},
"auth_ref": [
"r438"
]
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies"
],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Text Block]",
"documentation": "The entire disclosure for commitments and contingencies."
}
}
},
"auth_ref": [
"r76",
"r182",
"r183",
"r422",
"r482"
]
},
"us-gaap_DividendsCommonStockCash": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DividendsCommonStockCash",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_DividendsCommonStockCash",
"negatedLabel": "Cash dividends ($0.07 per share)",
"documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
}
}
},
"auth_ref": [
"r80"
]
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Hierarchy and NAV [Domain]",
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
}
}
},
"auth_ref": [
"r208",
"r234",
"r235",
"r236",
"r237",
"r238",
"r239",
"r329",
"r330",
"r331",
"r429",
"r430",
"r435",
"r436",
"r437"
]
},
"us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "ROU asset amortization",
"documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
}
}
},
"auth_ref": [
"r471"
]
},
"us-gaap_IncomeStatementAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncomeStatementAbstract",
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)",
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
}
}
},
"auth_ref": [
"r271"
]
},
"dei_DocumentInformationLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentInformationLineItems",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Document Information [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"pmd_statement-statement-note-10-revenue-tables": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-10-revenue-tables",
"lang": {
"en-us": {
"role": {
"label": "Note 10 - Revenue"
}
}
},
"auth_ref": []
},
"us-gaap_DeferredTaxAssetsValuationAllowance": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DeferredTaxAssetsValuationAllowance",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_DeferredTaxAssetsValuationAllowance",
"terseLabel": "Deferred Tax Assets, Valuation Allowance",
"documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
}
}
},
"auth_ref": [
"r284"
]
},
"us-gaap_StatementTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StatementTable",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals",
"http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables",
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "Statement [Table]",
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
}
}
},
"auth_ref": [
"r130",
"r131",
"r132",
"r155",
"r332",
"r365",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r379",
"r382",
"r383",
"r384",
"r385",
"r386",
"r388",
"r389",
"r390",
"r391",
"r393",
"r394",
"r395",
"r396",
"r397",
"r399",
"r401",
"r402",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r410",
"r411",
"r412",
"r413",
"r414",
"r415",
"r418",
"r446"
]
},
"pmd_statement-statement-note-3-fair-value-measurements-tables": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-3-fair-value-measurements-tables",
"lang": {
"en-us": {
"role": {
"label": "Note 3 - Fair Value Measurements"
}
}
},
"auth_ref": []
},
"us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
"negatedLabel": "Less: interest",
"documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
}
}
},
"auth_ref": [
"r327"
]
},
"pmd_statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details",
"lang": {
"en-us": {
"role": {
"label": "Note 3 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)"
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentType",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"us-gaap_Assets": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "Assets",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_Assets",
"totalLabel": "Total Assets",
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
}
}
},
"auth_ref": [
"r85",
"r108",
"r127",
"r156",
"r163",
"r167",
"r178",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r295",
"r297",
"r310",
"r335",
"r392",
"r441",
"r452",
"r485",
"r486",
"r520"
]
},
"us-gaap_DebtInstrumentAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DebtInstrumentAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Debt Instrument [Axis]",
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
}
}
},
"auth_ref": [
"r11",
"r51",
"r52",
"r86",
"r87",
"r129",
"r195",
"r196",
"r197",
"r198",
"r199",
"r201",
"r206",
"r207",
"r208",
"r209",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r318",
"r428",
"r429",
"r430",
"r431",
"r432",
"r472"
]
},
"pmd_IncentivePlan2006Member": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "IncentivePlan2006Member",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Incentive Plan 2006 [Member]",
"documentation": "Information related to the 2006 incentive plan."
}
}
},
"auth_ref": []
},
"us-gaap_EarningsPerShareBasic": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "EarningsPerShareBasic",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Basic net loss per share (in dollars per share)",
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
}
}
},
"auth_ref": [
"r120",
"r135",
"r136",
"r137",
"r138",
"r139",
"r144",
"r146",
"r148",
"r149",
"r150",
"r154",
"r306",
"r307",
"r333",
"r348",
"r425"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityFileNumber",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"pmd_statement-statement-note-10-revenue-revenue-by-major-source-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-10-revenue-revenue-by-major-source-details",
"lang": {
"en-us": {
"role": {
"label": "Note 10 - Revenue - Revenue by Major Source (Details)"
}
}
},
"auth_ref": []
},
"dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentQuarterlyReport",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report."
}
}
},
"auth_ref": [
"r456"
]
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Accumulated other comprehensive loss",
"documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
}
}
},
"auth_ref": [
"r22",
"r23",
"r60",
"r111",
"r341",
"r360",
"r361"
]
},
"pmd_LiquidityAndManagementsPlanPolicyTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "LiquidityAndManagementsPlanPolicyTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "Liquidity and Management's Plan [Policy Text Block]",
"documentation": "Disclosure of accounting policy for liquidity and management's plan."
}
}
},
"auth_ref": []
},
"srt_ProductOrServiceAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "ProductOrServiceAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Axis]"
}
}
},
"auth_ref": [
"r169",
"r332",
"r350",
"r351",
"r352",
"r353",
"r354",
"r355",
"r423",
"r433",
"r442",
"r463",
"r483",
"r484",
"r487",
"r524"
]
},
"us-gaap_OperatingLeaseLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseLiability",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"verboseLabel": "Operating Lease, Liability",
"label": "Present value of lease liabilities",
"terseLabel": "Operating Lease, Liability",
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
}
}
},
"auth_ref": [
"r321"
]
},
"pmd_IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes",
"terseLabel": "Accrued expenses",
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses and income taxes incurred but not yet paid."
}
}
},
"auth_ref": []
},
"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Accumulated depreciation and amortization",
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
}
}
},
"auth_ref": [
"r29",
"r106",
"r344"
]
},
"pmd_NoteToFinancialStatementDetailsTextual": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "NoteToFinancialStatementDetailsTextual",
"lang": {
"en-us": {
"role": {
"label": "Note To Financial Statement Details Textual"
}
}
},
"auth_ref": []
},
"us-gaap_GrossProfit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "GrossProfit",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_GrossProfit",
"totalLabel": "Gross profit",
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
}
}
},
"auth_ref": [
"r63",
"r127",
"r156",
"r162",
"r166",
"r168",
"r178",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r310",
"r427",
"r485"
]
},
"dei_DocumentTransitionReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentTransitionReport",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report."
}
}
},
"auth_ref": [
"r457"
]
},
"us-gaap_NetIncomeLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NetIncomeLoss",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 6.0
},
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Net loss",
"totalLabel": "Net loss",
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
}
}
},
"auth_ref": [
"r62",
"r71",
"r90",
"r101",
"r114",
"r115",
"r118",
"r127",
"r133",
"r135",
"r136",
"r137",
"r138",
"r141",
"r142",
"r147",
"r156",
"r162",
"r166",
"r168",
"r178",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r307",
"r310",
"r347",
"r400",
"r416",
"r417",
"r427",
"r451",
"r485"
]
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseLiabilityCurrent",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"label": "Current portion of operating lease liabilities",
"terseLabel": "Current operating lease liabilities",
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
}
}
},
"auth_ref": [
"r321"
]
},
"pmd_TestingMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "TestingMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details"
],
"lang": {
"en-us": {
"role": {
"label": "Testing [Member]",
"documentation": "Represents testing services."
}
}
},
"auth_ref": []
},
"srt_ProductsAndServicesDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "ProductsAndServicesDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Domain]"
}
}
},
"auth_ref": [
"r169",
"r332",
"r350",
"r351",
"r352",
"r353",
"r354",
"r355",
"r423",
"r433",
"r442",
"r463",
"r483",
"r484",
"r487",
"r524"
]
},
"pmd_NumberOfMajorCustomers": {
"xbrltype": "integerItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "NumberOfMajorCustomers",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_NumberOfMajorCustomers",
"terseLabel": "Number of Major Customers",
"documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc."
}
}
},
"auth_ref": []
},
"us-gaap_CommonStockSharesIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockSharesIssued",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Common stock, shares issued (in shares)",
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
}
}
},
"auth_ref": [
"r54"
]
},
"us-gaap_CommonStockMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock [Member]",
"documentation": "Stock that is subordinate to all other stock of the issuer."
}
}
},
"auth_ref": [
"r443",
"r444",
"r445",
"r447",
"r448",
"r449",
"r450",
"r476",
"r477",
"r515",
"r526",
"r528"
]
},
"pmd_NotesToFinancialStatementsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "NotesToFinancialStatementsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Notes To Financial Statements [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_EarningsPerShareDiluted": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "EarningsPerShareDiluted",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Diluted net loss per share (in dollars per share)",
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
}
}
},
"auth_ref": [
"r120",
"r135",
"r136",
"r137",
"r138",
"r139",
"r146",
"r148",
"r149",
"r150",
"r154",
"r306",
"r307",
"r333",
"r348",
"r425"
]
},
"us-gaap_AccruedLiabilitiesCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccruedLiabilitiesCurrent",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Accrued expenses",
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
}
}
},
"auth_ref": [
"r15"
]
},
"us-gaap_LongtermDebtTypeDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongtermDebtTypeDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details"
],
"lang": {
"en-us": {
"role": {
"label": "Long-Term Debt, Type [Domain]",
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
}
}
},
"auth_ref": [
"r17",
"r30"
]
},
"us-gaap_ResearchAndDevelopmentExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ResearchAndDevelopmentExpense",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Research & development",
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
}
}
},
"auth_ref": [
"r49",
"r277",
"r522"
]
},
"pmd_OtherRevenueMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "OtherRevenueMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details"
],
"lang": {
"en-us": {
"role": {
"label": "Other Revenue [Member]",
"documentation": "Represents other revenue sources not otherwise disclosed."
}
}
},
"auth_ref": []
},
"us-gaap_CommonStockValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockValue",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Common stock, $0.005 par value; 50,000 shares authorized; 6,470 and 6,349 shares issued and 5,802 and 5,681 shares outstanding, respectively",
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
}
}
},
"auth_ref": [
"r54",
"r340",
"r441"
]
},
"pmd_OtherNonoperatingExpenseSettlement": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "OtherNonoperatingExpenseSettlement",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_OtherNonoperatingExpenseSettlement",
"negatedLabel": "Settlement",
"documentation": "Amount of expense related to nonoperating activities, classified as settlement."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r454"
]
},
"pmd_CaliforniaLawsuitMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "CaliforniaLawsuitMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "California Lawsuit [Member]",
"documentation": "Related to the California lawsuit."
}
}
},
"auth_ref": []
},
"us-gaap_CommonStockSharesAuthorized": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockSharesAuthorized",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Common stock, shares authorized (in shares)",
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
}
}
},
"auth_ref": [
"r54",
"r379"
]
},
"us-gaap_PreferredStockSharesIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PreferredStockSharesIssued",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Preferred stock, shares issued (in shares)",
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
}
}
},
"auth_ref": [
"r53",
"r221"
]
},
"us-gaap_CommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockSharesOutstanding",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Common stock, shares outstanding (in shares)",
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
}
}
},
"auth_ref": [
"r8",
"r54",
"r379",
"r398",
"r528",
"r529"
]
},
"pmd_PaymentsOfEquipmentFinancing": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "PaymentsOfEquipmentFinancing",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_PaymentsOfEquipmentFinancing",
"negatedLabel": "Payments of equipment debt financing",
"documentation": "The cash outflow in relating to equity financing during the year."
}
}
},
"auth_ref": []
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseLiabilityNoncurrent",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Liabilities",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"verboseLabel": "Long-term portion of operating lease liabilities",
"label": "us-gaap_OperatingLeaseLiabilityNoncurrent",
"terseLabel": "Long-term operating lease liabilities",
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
}
}
},
"auth_ref": [
"r321"
]
},
"pmd_PaymentsForProceedsFromOtherAssets": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "PaymentsForProceedsFromOtherAssets",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_PaymentsForProceedsFromOtherAssets",
"negatedLabel": "Other assets",
"documentation": "The net cash outflow or inflow from other assets."
}
}
},
"auth_ref": []
},
"dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityInteractiveDataCurrent",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
}
}
},
"auth_ref": [
"r458"
]
},
"pmd_DepreciationAndAmortizationExcludingRouAssetAmortization": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "DepreciationAndAmortizationExcludingRouAssetAmortization",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 10.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Depreciation and amortization",
"documentation": "Amount of depreciation and amortization expense, excluding amortization expense for right-of-use asset from operating lease."
}
}
},
"auth_ref": []
},
"pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
"negatedTerseLabel": "Cancelled (in shares)",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period."
}
}
},
"auth_ref": []
},
"pmd_EnmaSagastumeVPsychemedicsCorporationMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "EnmaSagastumeVPsychemedicsCorporationMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Enma Sagastume v. Psychemedics Corporation [Member]",
"documentation": "Related to Enma Sagastume v. Psychemedics Corporation."
}
}
},
"auth_ref": []
},
"pmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod",
"negatedTerseLabel": "Converted to common stock (in shares)",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were converted to common stock during the reporting period."
}
}
},
"auth_ref": []
},
"pmd_EquipmentLoanArrangementMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "EquipmentLoanArrangementMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Equipment Loan Arrangement [Member]",
"documentation": "Information related to the Equipment Loan Arrangement."
}
}
},
"auth_ref": []
},
"pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Converted to common stock, weighted average price per share (in dollars per share)",
"documentation": "Weighted average price at which the instruments, excluding stock (or unit) options, that were converted to common stock during the reporting period"
}
}
},
"auth_ref": []
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding, weighted average remaining contractual life (Year)",
"documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
}
}
},
"auth_ref": [
"r81"
]
},
"pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Granted, weighted average price per share (in dollars per share)",
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of equity instrument other than option."
}
}
},
"auth_ref": []
},
"us-gaap_PreferredStockSharesAuthorized": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PreferredStockSharesAuthorized",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Preferred stock, shares authorized (in shares)",
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
}
}
},
"auth_ref": [
"r53",
"r379"
]
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Exercisable, weighted average remaining contractual life (Year)",
"documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
}
}
},
"auth_ref": [
"r35"
]
},
"pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice",
"periodStartLabel": "Outstanding & Unvested at beginning of period, weighted average price per share (in dollars per share)",
"periodEndLabel": "Outstanding & Unvested at end of period, weighted average price per share (in dollars per share)",
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the equity instrument other than option."
}
}
},
"auth_ref": []
},
"us-gaap_PreferredStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PreferredStockSharesOutstanding",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Preferred stock, shares outstanding (in shares)",
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
}
}
},
"auth_ref": [
"r53",
"r379",
"r398",
"r528",
"r529"
]
},
"us-gaap_Cash": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "Cash",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_Cash",
"terseLabel": "Cash",
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
}
}
},
"auth_ref": [
"r96",
"r338",
"r369",
"r387",
"r441",
"r452",
"r464"
]
},
"pmd_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Forfeited, weighted average price per share (in dollars per share)",
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to equity instrument other than stock options that were forfeited."
}
}
},
"auth_ref": []
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"totalLabel": "Weighted average common shares outstanding, diluted (in shares)",
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
}
}
},
"auth_ref": [
"r145",
"r150"
]
},
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AmendmentFlag",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"pmd_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Cancelled, weighted average price per share (in dollars per share)",
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to equity instrument other than stock options that were cancelled."
}
}
},
"auth_ref": []
},
"us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details": {
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details"
],
"lang": {
"en-us": {
"role": {
"label": "Dilutive common equivalent shares (in shares)",
"documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
}
}
},
"auth_ref": [
"r479"
]
},
"pmd_ChiefRevenueOfficerMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "ChiefRevenueOfficerMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Chief Revenue Officer [Member]",
"documentation": "Relating to the Chief Revenue Officer."
}
}
},
"auth_ref": []
},
"pmd_ShippingCollectionHairMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "ShippingCollectionHairMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details"
],
"lang": {
"en-us": {
"role": {
"label": "Shipping/Collection (Hair) [Member]",
"documentation": "Information pertaining to shipping and hair collection services."
}
}
},
"auth_ref": []
},
"us-gaap_StatementLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StatementLineItems",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals",
"http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables",
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "Statement [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r130",
"r131",
"r132",
"r155",
"r332",
"r365",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r379",
"r382",
"r383",
"r384",
"r385",
"r386",
"r388",
"r389",
"r390",
"r391",
"r393",
"r394",
"r395",
"r396",
"r397",
"r399",
"r401",
"r402",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r410",
"r411",
"r412",
"r413",
"r414",
"r415",
"r418",
"r446"
]
},
"us-gaap_ConcentrationRiskDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ConcentrationRiskDisclosureTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers"
],
"lang": {
"en-us": {
"role": {
"label": "Concentration Risk Disclosure [Text Block]",
"documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
}
}
},
"auth_ref": [
"r73"
]
},
"pmd_ChiefExecutiveOfficerAndPresidentMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "ChiefExecutiveOfficerAndPresidentMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Chief Executive Officer and President [Member]",
"documentation": "Represents chief executive officer and president."
}
}
},
"auth_ref": []
},
"us-gaap_CostOfGoodsAndServicesSold": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CostOfGoodsAndServicesSold",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Cost of revenues",
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
}
}
},
"auth_ref": [
"r64",
"r332"
]
},
"pmd_StockUnitAwardMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "StockUnitAwardMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Unit Award [Member]",
"documentation": "Related to stock unit awards."
}
}
},
"auth_ref": []
},
"srt_LitigationCaseTypeDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "LitigationCaseTypeDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Litigation Case [Domain]"
}
}
},
"auth_ref": []
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details": {
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted average common shares outstanding, basic (in shares)",
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
}
}
},
"auth_ref": [
"r144",
"r150"
]
},
"pmd_CustomerOneMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "CustomerOneMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Customer One [Member]",
"documentation": "Information related to customer one."
}
}
},
"auth_ref": []
},
"pmd_StockUnitAwardsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "StockUnitAwardsMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Unit Awards [Member]",
"documentation": "Information related to stock unit awards."
}
}
},
"auth_ref": []
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement [Text Block]",
"documentation": "The entire disclosure for share-based payment arrangement."
}
}
},
"auth_ref": [
"r240",
"r241",
"r269",
"r270",
"r272",
"r438"
]
},
"us-gaap_AdditionalPaidInCapitalCommonStock": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdditionalPaidInCapitalCommonStock",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Additional paid-in capital",
"documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
}
}
},
"auth_ref": [
"r55"
]
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent",
"terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent",
"documentation": "Weighted average discount rate for operating lease calculated at point in time."
}
}
},
"auth_ref": [
"r326",
"r440"
]
},
"us-gaap_OperatingExpenses": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingExpenses",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_OperatingExpenses",
"totalLabel": "Total Operating expenses",
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
}
}
},
"auth_ref": []
},
"us-gaap_TableTextBlock": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "TableTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_TableTextBlock",
"terseLabel": "Notes Tables"
}
}
},
"auth_ref": []
},
"us-gaap_CreditFacilityDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CreditFacilityDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Credit Facility [Domain]",
"documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
}
}
},
"auth_ref": []
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseRightOfUseAsset",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Operating lease right-of-use assets",
"terseLabel": "Operating Lease, Right-of-Use Asset",
"documentation": "Amount of lessee's right to use underlying asset under operating lease."
}
}
},
"auth_ref": [
"r320"
]
},
"dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentFiscalYearFocus",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
}
}
},
"auth_ref": []
},
"us-gaap_CommonStockDividendsPerShareDeclared": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockDividendsPerShareDeclared",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Cash dividends declared (in dollars per share)",
"documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
}
}
},
"auth_ref": [
"r80"
]
},
"dei_EntitySmallBusiness": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntitySmallBusiness",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
}
}
},
"auth_ref": [
"r454"
]
},
"us-gaap_DebtDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DebtDisclosureTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt"
],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Text Block]",
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
}
}
},
"auth_ref": [
"r77",
"r126",
"r194",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r210",
"r217",
"r218",
"r219"
]
},
"us-gaap_AdditionalPaidInCapitalMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdditionalPaidInCapitalMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Additional Paid-in Capital [Member]",
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
}
}
},
"auth_ref": [
"r273",
"r274",
"r275",
"r368",
"r476",
"r477",
"r478",
"r515",
"r528"
]
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CashAndCashEquivalentsAtCarryingValue",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Cash and cash equivalents",
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
}
}
},
"auth_ref": [
"r25",
"r104",
"r424"
]
},
"us-gaap_SalesRevenueNetMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SalesRevenueNetMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Revenue Benchmark [Member]",
"documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
}
}
},
"auth_ref": [
"r171",
"r460"
]
},
"us-gaap_PolicyTextBlockAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PolicyTextBlockAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_PolicyTextBlockAbstract",
"terseLabel": "Accounting Policies"
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentFiscalPeriodFocus",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
}
}
},
"auth_ref": []
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r454"
]
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueByFairValueHierarchyLevelAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Hierarchy and NAV [Axis]",
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
}
}
},
"auth_ref": [
"r208",
"r234",
"r235",
"r236",
"r237",
"r238",
"r239",
"r309",
"r329",
"r330",
"r331",
"r429",
"r430",
"r435",
"r436",
"r437"
]
},
"us-gaap_NonoperatingIncomeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NonoperatingIncomeExpense",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_NonoperatingIncomeExpense",
"totalLabel": "Total other income (expense), net",
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
}
}
},
"auth_ref": [
"r66"
]
},
"us-gaap_AccountingPoliciesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccountingPoliciesAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_LesseeOperatingLeasesTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeasesTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-"
],
"lang": {
"en-us": {
"role": {
"label": "Lessee, Operating Leases [Text Block]",
"documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
}
}
},
"auth_ref": [
"r319"
]
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)",
"documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement."
}
}
},
"auth_ref": []
},
"us-gaap_FairValueInputsLevel2Member": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueInputsLevel2Member",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Inputs, Level 2 [Member]",
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
}
}
},
"auth_ref": [
"r208",
"r234",
"r239",
"r309",
"r330",
"r429",
"r430",
"r435",
"r436",
"r437"
]
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Granted, weighted average exercise price (in dollars per share)",
"terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)",
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
}
}
},
"auth_ref": [
"r249"
]
},
"us-gaap_FairValueInputsLevel1Member": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueInputsLevel1Member",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Inputs, Level 1 [Member]",
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
}
}
},
"auth_ref": [
"r208",
"r234",
"r239",
"r309",
"r329",
"r435",
"r436",
"r437"
]
},
"pmd_statement-statement-note-4-stockbased-compensation-compensation-cost-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-4-stockbased-compensation-compensation-cost-details",
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Stock-based Compensation - Compensation Cost (Details)"
}
}
},
"auth_ref": []
},
"pmd_statement-statement-note-4-stockbased-compensation-nonvested-award-activity-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-4-stockbased-compensation-nonvested-award-activity-details",
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Stock-based Compensation - Nonvested Award Activity (Details)"
}
}
},
"auth_ref": []
},
"pmd_statement-statement-note-4-stockbased-compensation-stock-option-activity-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-4-stockbased-compensation-stock-option-activity-details",
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Stock-based Compensation - Stock Option Activity (Details)"
}
}
},
"auth_ref": []
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"totalLabel": "Total lease payments",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
}
}
},
"auth_ref": [
"r327"
]
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)",
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
}
}
},
"auth_ref": [
"r325",
"r440"
]
},
"pmd_statement-statement-note-4-stockbased-compensation-tables": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-4-stockbased-compensation-tables",
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Stock-based Compensation"
}
}
},
"auth_ref": []
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Canceled, weighted average exercise price (in dollars per share)",
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
}
}
},
"auth_ref": [
"r252"
]
},
"pmd_statement-statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details",
"lang": {
"en-us": {
"role": {
"label": "Note 6 - Basic and Diluted Net Loss Per Share - Basic and Diluted Weighted Average Common Shares Outstanding (Details)"
}
}
},
"auth_ref": []
},
"us-gaap_StatementEquityComponentsAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StatementEquityComponentsAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Components [Axis]",
"documentation": "Information by component of equity."
}
}
},
"auth_ref": [
"r8",
"r20",
"r100",
"r116",
"r117",
"r118",
"r130",
"r131",
"r132",
"r134",
"r140",
"r142",
"r155",
"r179",
"r180",
"r222",
"r273",
"r274",
"r275",
"r286",
"r287",
"r299",
"r300",
"r301",
"r302",
"r303",
"r304",
"r305",
"r311",
"r312",
"r313",
"r314",
"r315",
"r316",
"r328",
"r356",
"r357",
"r358",
"r368",
"r418"
]
},
"us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationAwardTrancheOneMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Tranche One [Member]",
"documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
}
}
},
"auth_ref": []
},
"us-gaap_FairValueInputsLevel3Member": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueInputsLevel3Member",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Inputs, Level 3 [Member]",
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
}
}
},
"auth_ref": [
"r208",
"r234",
"r235",
"r236",
"r237",
"r238",
"r239",
"r309",
"r331",
"r429",
"r430",
"r435",
"r436",
"r437"
]
},
"pmd_statement-statement-note-6-basic-and-diluted-net-loss-per-share-tables": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-6-basic-and-diluted-net-loss-per-share-tables",
"lang": {
"en-us": {
"role": {
"label": "Note 6 - Basic and Diluted Net Loss Per Share"
}
}
},
"auth_ref": []
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Forfeited, weighted average exercise price (in dollars per share)",
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
}
}
},
"auth_ref": [
"r251"
]
},
"us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details"
],
"lang": {
"en-us": {
"role": {
"label": "Revenues",
"terseLabel": "Revenues",
"documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
}
}
},
"auth_ref": [
"r157",
"r158",
"r161",
"r164",
"r165",
"r169",
"r170",
"r171",
"r231",
"r232",
"r332"
]
},
"pmd_statement-statement-note-8-operating-leases-maturities-of-lease-liabilities-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-8-operating-leases-maturities-of-lease-liabilities-details",
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Operating Leases - Maturities of Lease Liabilities (Details)"
}
}
},
"auth_ref": []
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details": {
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"terseLabel": "2024",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
}
}
},
"auth_ref": [
"r327"
]
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockParOrStatedValuePerShare",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Common stock, par value (in dollars per share)",
"documentation": "Face amount or stated value per share of common stock."
}
}
},
"auth_ref": [
"r54"
]
},
"us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Right-of-use assets acquired through operating leases",
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
}
}
},
"auth_ref": [
"r324",
"r440"
]
},
"us-gaap_EarningsPerShareTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "EarningsPerShareTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Text Block]",
"documentation": "The entire disclosure for earnings per share."
}
}
},
"auth_ref": [
"r143",
"r151",
"r152",
"r153"
]
},
"us-gaap_RetainedEarningsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RetainedEarningsMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Retained Earnings [Member]",
"documentation": "Accumulated undistributed earnings (deficit)."
}
}
},
"auth_ref": [
"r100",
"r130",
"r131",
"r132",
"r134",
"r140",
"r142",
"r179",
"r180",
"r273",
"r274",
"r275",
"r286",
"r287",
"r299",
"r301",
"r302",
"r304",
"r305",
"r356",
"r358",
"r368",
"r528"
]
},
"us-gaap_SharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SharesOutstanding",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_SharesOutstanding",
"periodStartLabel": "Balance (in shares)",
"periodEndLabel": "Balance (in shares)",
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
}
}
},
"auth_ref": []
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)",
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
}
}
},
"auth_ref": [
"r151"
]
},
"pmd_statement-statement-note-8-operating-leases-tables": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-8-operating-leases-tables",
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Operating Leases"
}
}
},
"auth_ref": []
},
"pmd_statement-statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"lang": {
"en-us": {
"role": {
"label": "Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)"
}
}
},
"auth_ref": []
},
"pmd_statement-statement-note-9-debt-tables": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-note-9-debt-tables",
"lang": {
"en-us": {
"role": {
"label": "Note 9 - Debt"
}
}
},
"auth_ref": []
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
"negatedLabel": "Shares issued \u2013 vested",
"documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
}
}
},
"auth_ref": [
"r260"
]
},
"us-gaap_OtherAssetsNoncurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OtherAssetsNoncurrent",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Other assets",
"documentation": "Amount of noncurrent assets classified as other."
}
}
},
"auth_ref": [
"r107"
]
},
"us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationAwardTrancheThreeMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Tranche Three [Member]",
"documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
}
}
},
"auth_ref": []
},
"pmd_statement-statement-significant-accounting-policies-policies": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "statement-statement-significant-accounting-policies-policies",
"lang": {
"en-us": {
"role": {
"label": "Significant Accounting Policies"
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"us-gaap_CommonStockDividendsPerShareCashPaid": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockDividendsPerShareCashPaid",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Dividends declared per share (in dollars per share)",
"documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
}
}
},
"auth_ref": [
"r80"
]
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details": {
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
"terseLabel": "2026",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
}
}
},
"auth_ref": [
"r327"
]
},
"us-gaap_PaymentsToDevelopSoftware": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PaymentsToDevelopSoftware",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_PaymentsToDevelopSoftware",
"negatedLabel": "Cost of internally developed software",
"documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization."
}
}
},
"auth_ref": [
"r68"
]
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Loss before provision for (benefit from) income taxes",
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
}
}
},
"auth_ref": [
"r0",
"r61",
"r89",
"r156",
"r162",
"r166",
"r168",
"r334",
"r346",
"r427"
]
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details": {
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
"terseLabel": "2025",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
}
}
},
"auth_ref": [
"r327"
]
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Exercise of stock options",
"documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
}
}
},
"auth_ref": [
"r8",
"r80"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"negatedTerseLabel": "Forfeited (in shares)",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
}
}
},
"auth_ref": [
"r258"
]
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details": {
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"terseLabel": "October 1, 2023, through December 31, 2023",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
}
}
},
"auth_ref": [
"r518"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"terseLabel": "Shares issued \u2013 vested (in shares)",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
}
}
},
"auth_ref": [
"r257"
]
},
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
}
}
},
"auth_ref": [
"r518"
]
},
"us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationAwardTrancheTwoMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Tranche Two [Member]",
"documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
}
}
},
"auth_ref": []
},
"us-gaap_OperatingLeaseExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeaseExpense",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_OperatingLeaseExpense",
"terseLabel": "Operating Lease, Expense",
"documentation": "Amount of operating lease expense. Excludes sublease income."
}
}
},
"auth_ref": [
"r517"
]
},
"us-gaap_AccountsReceivableMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccountsReceivableMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Accounts Receivable [Member]",
"documentation": "Due from customers or clients for goods or services that have been delivered or sold."
}
}
},
"auth_ref": [
"r421"
]
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Prepaid expenses and other current assets",
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
}
}
},
"auth_ref": [
"r466"
]
},
"us-gaap_EquityComponentDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "EquityComponentDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Component [Domain]",
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
}
}
},
"auth_ref": [
"r8",
"r100",
"r116",
"r117",
"r118",
"r130",
"r131",
"r132",
"r134",
"r140",
"r142",
"r155",
"r179",
"r180",
"r222",
"r273",
"r274",
"r275",
"r286",
"r287",
"r299",
"r300",
"r301",
"r302",
"r303",
"r304",
"r305",
"r311",
"r312",
"r313",
"r314",
"r315",
"r316",
"r328",
"r356",
"r357",
"r358",
"r368",
"r418"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"periodStartLabel": "Outstanding & Unvested at beginning of period (in shares)",
"periodEndLabel": "Outstanding & Unvested at end of period (in shares)",
"documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
}
}
},
"auth_ref": [
"r253",
"r254"
]
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AllocatedShareBasedCompensationExpense",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details"
],
"lang": {
"en-us": {
"role": {
"label": "Share-based compensation",
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
}
}
},
"auth_ref": [
"r268",
"r276"
]
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "AOCI Attributable to Parent [Member]",
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
}
}
},
"auth_ref": [
"r2",
"r7",
"r23",
"r300",
"r303",
"r328",
"r356",
"r357",
"r467",
"r468",
"r469",
"r476",
"r477",
"r478"
]
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
"documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
}
}
},
"auth_ref": [
"r39",
"r84"
]
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
"terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
"documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r271"
]
},
"us-gaap_OperatingExpensesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingExpensesAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Operating expenses:"
}
}
},
"auth_ref": []
},
"us-gaap_ShareBasedCompensation": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensation",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensation",
"terseLabel": "Stock-based compensation",
"documentation": "Amount of noncash expense for share-based payment arrangement."
}
}
},
"auth_ref": [
"r4"
]
},
"us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInIncomeTaxesReceivable",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0,
"order": 7.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable",
"negatedTerseLabel": "Income tax receivable",
"documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
}
}
},
"auth_ref": [
"r4"
]
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": {
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"terseLabel": "October 1, 2023, through December 31, 2023",
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
}
}
},
"auth_ref": [
"r475"
]
},
"us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information"
],
"lang": {
"en-us": {
"role": {
"label": "Business Description and Accounting Policies [Text Block]",
"documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
}
}
},
"auth_ref": [
"r72",
"r73"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)",
"documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
}
}
},
"auth_ref": [
"r35"
]
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInAccountsReceivable",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
"negatedLabel": "Accounts receivable",
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
}
}
},
"auth_ref": [
"r4"
]
},
"us-gaap_InterestPaidNet": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "InterestPaidNet",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Cash paid for interest",
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
}
}
},
"auth_ref": [
"r121",
"r123",
"r124"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
"negatedLabel": "Canceled, shares (in shares)",
"documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
}
}
},
"auth_ref": [
"r252"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"negatedLabel": "Forfeited, shares (in shares)",
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
}
}
},
"auth_ref": [
"r251"
]
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Cash equivalents, fair value",
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
}
}
},
"auth_ref": []
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
"periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
}
}
},
"auth_ref": [
"r245",
"r246"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"periodStartLabel": "Outstanding, shares (in shares)",
"periodEndLabel": "Outstanding, shares (in shares)",
"documentation": "Number of options outstanding, including both vested and non-vested options."
}
}
},
"auth_ref": [
"r245",
"r246"
]
},
"us-gaap_DisclosureTextBlockAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DisclosureTextBlockAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_DisclosureTextBlockAbstract",
"terseLabel": "Notes to Financial Statements"
}
}
},
"auth_ref": []
},
"us-gaap_AccountsPayableCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccountsPayableCurrent",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Accounts payable",
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
}
}
},
"auth_ref": [
"r12",
"r441"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding, aggregate intrinsic value",
"documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
}
}
},
"auth_ref": [
"r35"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Exercisable, shares (in shares)",
"documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
}
}
},
"auth_ref": [
"r247"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Exercisable, weighted average exercise price (in dollars per share)",
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
}
}
},
"auth_ref": [
"r247"
]
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"us-gaap_ConcentrationRiskByTypeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ConcentrationRiskByTypeAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Concentration Risk Type [Axis]",
"documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
}
}
},
"auth_ref": [
"r26",
"r28",
"r40",
"r41",
"r171",
"r421",
"r461"
]
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PreferredStockParOrStatedValuePerShare",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Preferred stock, par value (in dollars per share)",
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
}
}
},
"auth_ref": [
"r53",
"r221"
]
},
"us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfDebtInstrumentsTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
"documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
}
}
},
"auth_ref": [
"r17",
"r31",
"r32",
"r42",
"r43",
"r45",
"r48",
"r78",
"r79",
"r429",
"r431",
"r475"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
"terseLabel": "Share-Based Payment Arrangement, Accelerated Cost",
"documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
}
}
},
"auth_ref": []
},
"us-gaap_IncomeTaxesReceivable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncomeTaxesReceivable",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Income tax receivable",
"documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
}
}
},
"auth_ref": [
"r46",
"r465"
]
},
"us-gaap_StockholdersEquityAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StockholdersEquityAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Shareholders' Equity:"
}
}
},
"auth_ref": []
},
"us-gaap_LongTermDebt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongTermDebt",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LongTermDebt",
"terseLabel": "Long-Term Debt",
"totalLabel": "Long-term debt from equipment financing",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
}
}
},
"auth_ref": [
"r11",
"r87",
"r207",
"r220",
"r429",
"r430",
"r523"
]
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation"
],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
}
}
},
"auth_ref": [
"r50",
"r83",
"r363",
"r364"
]
},
"us-gaap_EmployeeStockOptionMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "EmployeeStockOptionMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Option [Member]",
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Changes in operating assets and liabilities:"
}
}
},
"auth_ref": []
},
"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Cash and Cash Equivalents [Domain]",
"documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
}
}
},
"auth_ref": [
"r104"
]
},
"us-gaap_IncreaseDecreaseInAccountsPayable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInAccountsPayable",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 8.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_IncreaseDecreaseInAccountsPayable",
"terseLabel": "Accounts payable",
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
}
}
},
"auth_ref": [
"r4"
]
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Award Type [Domain]",
"documentation": "Award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r242",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r261",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267"
]
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"totalLabel": "Net decrease in cash and cash equivalents",
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
}
}
},
"auth_ref": [
"r1",
"r69"
]
},
"us-gaap_PreferredStockValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PreferredStockValue",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding",
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
}
}
},
"auth_ref": [
"r53",
"r339",
"r441"
]
},
"us-gaap_DisaggregationOfRevenueTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DisaggregationOfRevenueTableTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Disaggregation of Revenue [Table Text Block]",
"documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
}
}
},
"auth_ref": [
"r487"
]
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"periodStartLabel": "Cash and cash equivalents, beginning of period",
"periodEndLabel": "Cash and cash equivalents, end of period",
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
}
}
},
"auth_ref": [
"r25",
"r69",
"r125"
]
},
"us-gaap_AccountsReceivableNetCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AccountsReceivableNetCurrent",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Accounts receivable, net of allowance for doubtful accounts of $38 at September 30, 2023, and $87 at December 31, 2022",
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
}
}
},
"auth_ref": [
"r172",
"r173"
]
},
"us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
"negatedLabel": "Tax withholding related to vested shares from employee stock plans",
"documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
}
}
},
"auth_ref": []
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StatementOfFinancialPositionAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
}
}
},
"auth_ref": [
"r479"
]
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CityAreaCode",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"us-gaap_LongTermDebtCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongTermDebtCurrent",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details"
],
"lang": {
"en-us": {
"role": {
"label": "Current portion of long-term debt",
"negatedTerseLabel": "Less: current portion of long-term debt from equipment financing",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
}
}
},
"auth_ref": [
"r109"
]
},
"us-gaap_AssetsCurrentAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AssetsCurrentAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Current Assets:"
}
}
},
"auth_ref": []
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Exercisable, aggregate intrinsic value",
"documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
}
}
},
"auth_ref": [
"r35"
]
},
"us-gaap_VestingAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "VestingAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Vesting [Axis]",
"documentation": "Information by vesting schedule of award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r489",
"r490",
"r491",
"r492",
"r493",
"r494",
"r495",
"r496",
"r497",
"r498",
"r499",
"r500",
"r501",
"r502",
"r503",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r511",
"r512",
"r513",
"r514"
]
},
"us-gaap_StockholdersEquity": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StockholdersEquity",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_StockholdersEquity",
"totalLabel": "Total Shareholders' Equity",
"periodStartLabel": "Balance",
"periodEndLabel": "Balance",
"documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
}
}
},
"auth_ref": [
"r54",
"r57",
"r58",
"r74",
"r381",
"r398",
"r419",
"r420",
"r441",
"r452",
"r473",
"r481",
"r516",
"r528"
]
},
"us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Allowance for doubtful accounts",
"documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
}
}
},
"auth_ref": [
"r112",
"r176",
"r181"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "LocalPhoneNumber",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Domain]"
}
}
},
"auth_ref": []
},
"us-gaap_DeferredIncomeTaxAssetsNet": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DeferredIncomeTaxAssetsNet",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Net deferred tax assets",
"documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
}
}
},
"auth_ref": [
"r279",
"r280"
]
},
"us-gaap_Liabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "Liabilities",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_Liabilities",
"totalLabel": "Total Liabilities",
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
}
}
},
"auth_ref": [
"r14",
"r127",
"r178",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r296",
"r297",
"r298",
"r310",
"r377",
"r426",
"r452",
"r485",
"r520",
"r521"
]
},
"us-gaap_VestingDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "VestingDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Vesting [Domain]",
"documentation": "Vesting schedule of award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r489",
"r490",
"r491",
"r492",
"r493",
"r494",
"r495",
"r496",
"r497",
"r498",
"r499",
"r500",
"r501",
"r502",
"r503",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r511",
"r512",
"r513",
"r514"
]
},
"us-gaap_OperatingIncomeLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingIncomeLoss",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_OperatingIncomeLoss",
"totalLabel": "Operating loss",
"documentation": "The net result for the period of deducting operating expenses from operating revenues."
}
}
},
"auth_ref": [
"r156",
"r162",
"r166",
"r168",
"r427"
]
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": {
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
"terseLabel": "2024",
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
}
}
},
"auth_ref": [
"r6",
"r129",
"r212"
]
},
"us-gaap_LossContingencyAccrualAtCarryingValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LossContingencyAccrualAtCarryingValue",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LossContingencyAccrualAtCarryingValue",
"terseLabel": "Loss Contingency Accrual",
"documentation": "Amount of loss contingency liability."
}
}
},
"auth_ref": [
"r184",
"r459"
]
},
"us-gaap_IncomeTaxExpenseBenefit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncomeTaxExpenseBenefit",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Provision for (benefit from) income taxes",
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
}
}
},
"auth_ref": [
"r95",
"r98",
"r141",
"r142",
"r160",
"r281",
"r289",
"r349"
]
},
"pmd_BancOfAmericaLeasingAndCapitalMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psychemedics.com/20230930",
"localname": "BancOfAmericaLeasingAndCapitalMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Banc of America Leasing and Capital [Member]",
"documentation": "Informaiton related to an equipment financing agreement with Banc of America Leasing and Capital LLC."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"srt_MajorCustomersAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "MajorCustomersAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Axis]"
}
}
},
"auth_ref": [
"r171",
"r434",
"r487",
"r524",
"r525"
]
},
"srt_TitleOfIndividualAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "TitleOfIndividualAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Axis]"
}
}
},
"auth_ref": [
"r480",
"r519"
]
},
"us-gaap_ConcentrationRiskPercentage1": {
"xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ConcentrationRiskPercentage1",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_ConcentrationRiskPercentage1",
"terseLabel": "Concentration Risk, Percentage",
"documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
}
}
},
"auth_ref": [
"r26",
"r28",
"r40",
"r41",
"r171"
]
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RevenueFromContractWithCustomerTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue"
],
"lang": {
"en-us": {
"role": {
"label": "Revenue from Contract with Customer [Text Block]",
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
}
}
},
"auth_ref": [
"r99",
"r223",
"r224",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r233"
]
},
"us-gaap_LongTermDebtNoncurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongTermDebtNoncurrent",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Liabilities",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details"
],
"lang": {
"en-us": {
"role": {
"verboseLabel": "Long-term debt",
"label": "us-gaap_LongTermDebtNoncurrent",
"terseLabel": "Long-term debt from equipment financing, net of current portion",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
}
}
},
"auth_ref": [
"r110"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "Security12bTitle",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r453"
]
},
"us-gaap_DebtInstrumentNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DebtInstrumentNameDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Debt Instrument, Name [Domain]",
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
}
}
},
"auth_ref": [
"r17",
"r129",
"r195",
"r196",
"r197",
"r198",
"r199",
"r201",
"r206",
"r207",
"r208",
"r209",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r318",
"r428",
"r429",
"r430",
"r431",
"r432",
"r472"
]
},
"srt_NameOfMajorCustomerDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "NameOfMajorCustomerDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Domain]"
}
}
},
"auth_ref": [
"r171",
"r434",
"r487",
"r524",
"r525"
]
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LiabilitiesAndStockholdersEquity",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LiabilitiesAndStockholdersEquity",
"totalLabel": "Total Liabilities and Shareholders' Equity",
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
}
}
},
"auth_ref": [
"r59",
"r88",
"r343",
"r441",
"r473",
"r481",
"r516"
]
},
"us-gaap_TreasuryStockCommonMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "TreasuryStockCommonMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Treasury Stock, Common [Member]",
"documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
}
}
},
"auth_ref": [
"r33"
]
},
"us-gaap_OperatingLeasePayments": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OperatingLeasePayments",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Cash paid for operating leases",
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
}
}
},
"auth_ref": [
"r322",
"r323"
]
},
"us-gaap_InterestExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "InterestExpense",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_InterestExpense",
"terseLabel": "Interest Expense",
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
}
}
},
"auth_ref": [
"r44",
"r91",
"r119",
"r159",
"r317",
"r403",
"r451",
"r527"
]
},
"us-gaap_DeferredIncomeTaxExpenseBenefit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DeferredIncomeTaxExpenseBenefit",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Deferred income taxes",
"documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
}
}
},
"auth_ref": [
"r5",
"r82",
"r97",
"r290",
"r291",
"r474"
]
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_DocumentInformationTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "DocumentInformationTable",
"lang": {
"en-us": {
"role": {
"label": "Document Information [Table]",
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
}
}
},
"auth_ref": []
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
"negatedLabel": "Purchases of equipment and leasehold improvements",
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
}
}
},
"auth_ref": [
"r68"
]
},
"us-gaap_LineOfCreditFacilityLenderDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LineOfCreditFacilityLenderDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Line of Credit Facility, Lender [Domain]",
"documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
}
}
},
"auth_ref": [
"r13",
"r472"
]
},
"us-gaap_SellingAndMarketingExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SellingAndMarketingExpense",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Marketing & selling",
"documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityRegistrantName",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r454"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "TradingSymbol",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"us-gaap_TreasuryStockCommonShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "TreasuryStockCommonShares",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"lang": {
"en-us": {
"role": {
"label": "Treasury stock, shares (in shares)",
"documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
}
}
},
"auth_ref": [
"r33"
]
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
}
}
},
"auth_ref": []
},
"dei_LegalEntityAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "LegalEntityAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information",
"http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables",
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "Legal Entity [Axis]",
"documentation": "The set of legal entities associated with a report."
}
}
},
"auth_ref": []
},
"us-gaap_LongtermDebtTypeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongtermDebtTypeAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details"
],
"lang": {
"en-us": {
"role": {
"label": "Long-Term Debt, Type [Axis]",
"documentation": "Information by type of long-term debt."
}
}
},
"auth_ref": [
"r17"
]
},
"us-gaap_TreasuryStockCommonValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "TreasuryStockCommonValue",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_StockholdersEquity",
"weight": -1.0,
"order": 5.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_TreasuryStockCommonValue",
"negatedLabel": "Less - Treasury stock, at cost, 668 shares",
"documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
}
}
},
"auth_ref": [
"r21",
"r33",
"r34"
]
},
"us-gaap_FairValueDisclosuresTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueDisclosuresTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Text Block]",
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
}
}
},
"auth_ref": [
"r308"
]
},
"us-gaap_PlanNameAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PlanNameAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Plan Name [Axis]",
"documentation": "Information by plan name for share-based payment arrangement."
}
}
},
"auth_ref": [
"r489",
"r490",
"r491",
"r492",
"r493",
"r494",
"r495",
"r496",
"r497",
"r498",
"r499",
"r500",
"r501",
"r502",
"r503",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r511",
"r512",
"r513",
"r514"
]
},
"us-gaap_ConcentrationRiskTypeDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ConcentrationRiskTypeDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Concentration Risk Type [Domain]",
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
}
}
},
"auth_ref": [
"r26",
"r28",
"r40",
"r41",
"r171",
"r421"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "SecurityExchangeName",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r455"
]
},
"dei_EntityDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information",
"http://www.psychemedics.com/20230930/role/statement-note-1-basis-of-presentation",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-revenue-by-major-source-details",
"http://www.psychemedics.com/20230930/role/statement-note-10-revenue-tables",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information",
"http://www.psychemedics.com/20230930/role/statement-note-2-financial-information-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details",
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-tables",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes",
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-basic-and-diluted-weighted-average-common-shares-outstanding-details",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-6-basic-and-diluted-net-loss-per-share-tables",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-maturities-of-lease-liabilities-details",
"http://www.psychemedics.com/20230930/role/statement-note-8-operating-leases-tables",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-tables",
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "Entity [Domain]",
"documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
}
}
},
"auth_ref": []
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
}
}
},
"auth_ref": [
"r9",
"r10",
"r36"
]
},
"us-gaap_LineOfCreditFacilityAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LineOfCreditFacilityAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Lender Name [Axis]",
"documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
}
}
},
"auth_ref": [
"r13",
"r472"
]
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Accumulated deficit",
"documentation": "Amount of accumulated undistributed earnings (deficit)."
}
}
},
"auth_ref": [
"r56",
"r80",
"r342",
"r359",
"r361",
"r366",
"r380",
"r441"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Granted (in shares)",
"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
}
}
},
"auth_ref": [
"r256"
]
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
"crdr": "credit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"verboseLabel": "Stock-based compensation",
"label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
}
}
},
"auth_ref": []
},
"us-gaap_LitigationSettlementExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LitigationSettlementExpense",
"crdr": "debit",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LitigationSettlementExpense",
"terseLabel": "Litigation Settlement, Expense",
"documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
}
}
},
"auth_ref": []
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r454"
]
},
"us-gaap_PlanNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PlanNameDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Plan Name [Domain]",
"documentation": "Plan name for share-based payment arrangement."
}
}
},
"auth_ref": [
"r489",
"r490",
"r491",
"r492",
"r493",
"r494",
"r495",
"r496",
"r497",
"r498",
"r499",
"r500",
"r501",
"r502",
"r503",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r511",
"r512",
"r513",
"r514"
]
},
"dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityCommonStockSharesOutstanding",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
}
}
},
"auth_ref": []
},
"us-gaap_LiabilitiesCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LiabilitiesCurrent",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Liabilities",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LiabilitiesCurrent",
"totalLabel": "Total Current Liabilities",
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
}
}
},
"auth_ref": [
"r16",
"r103",
"r127",
"r178",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r296",
"r297",
"r298",
"r310",
"r441",
"r485",
"r520",
"r521"
]
},
"us-gaap_MoneyMarketFundsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "MoneyMarketFundsMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Money Market Funds [Member]",
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
}
}
},
"auth_ref": [
"r488"
]
},
"us-gaap_CustomerConcentrationRiskMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CustomerConcentrationRiskMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Customer Concentration Risk [Member]",
"documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
}
}
},
"auth_ref": [
"r27",
"r171"
]
},
"us-gaap_LongtermDebtWeightedAverageInterestRate": {
"xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LongtermDebtWeightedAverageInterestRate",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_LongtermDebtWeightedAverageInterestRate",
"terseLabel": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
"documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time."
}
}
},
"auth_ref": []
},
"us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommonStockCapitalSharesReservedForFutureIssuance",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
"terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)",
"documentation": "Aggregate number of common shares reserved for future issuance."
}
}
},
"auth_ref": [
"r19"
]
},
"us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DeferredIncomeTaxLiabilitiesNet",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Liabilities",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Deferred tax liabilities, long-term",
"documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
}
}
},
"auth_ref": [
"r279",
"r280",
"r336"
]
},
"us-gaap_AwardTypeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AwardTypeAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-compensation-cost-details",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-nonvested-award-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Award Type [Axis]",
"documentation": "Information by type of award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r242",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r261",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267"
]
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StatementOfStockholdersEquityAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"us-gaap_StatementOfCashFlowsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StatementOfCashFlowsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"auth_ref": []
},
"dei_CurrentFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "CurrentFiscalYearEndDate",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD."
}
}
},
"auth_ref": []
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NetCashProvidedByUsedInFinancingActivities",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"totalLabel": "Net cash used in financing activities",
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
}
}
},
"auth_ref": [
"r122"
]
},
"us-gaap_LineOfCreditMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LineOfCreditMember",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Line of Credit [Member]",
"documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
}
}
},
"auth_ref": []
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
}
}
},
"auth_ref": []
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Exercise of stock options (in shares)",
"documentation": "Number of share options (or share units) exercised during the current period."
}
}
},
"auth_ref": [
"r8",
"r53",
"r54",
"r80",
"r250"
]
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncomeTaxDisclosureTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-5-income-taxes"
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Text Block]",
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
}
}
},
"auth_ref": [
"r128",
"r278",
"r282",
"r283",
"r285",
"r288",
"r292",
"r293",
"r294",
"r367"
]
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NetCashProvidedByUsedInInvestingActivities",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"totalLabel": "Net cash used in investing activities",
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
}
}
},
"auth_ref": [
"r122"
]
},
"us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInOperatingLeaseLiability",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 9.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability",
"terseLabel": "Operating lease liabilities",
"documentation": "Amount of increase (decrease) in obligation for operating lease."
}
}
},
"auth_ref": [
"r462",
"r470"
]
},
"us-gaap_SupplementalCashFlowInformationAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SupplementalCashFlowInformationAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Supplemental Disclosures of Cash Flow Information:"
}
}
},
"auth_ref": []
},
"us-gaap_GeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "GeneralAndAdministrativeExpense",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "General & administrative",
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
}
}
},
"auth_ref": [
"r65",
"r402"
]
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
}
}
},
"auth_ref": []
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NetCashProvidedByUsedInOperatingActivities",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"totalLabel": "Net cash used in operating activities",
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
}
}
},
"auth_ref": [
"r69",
"r70",
"r71"
]
},
"us-gaap_LiabilitiesCurrentAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LiabilitiesCurrentAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Current Liabilities:"
}
}
},
"auth_ref": []
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
}
}
},
"auth_ref": []
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0,
"order": 5.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"negatedLabel": "Prepaid expenses and other current assets",
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
}
}
},
"auth_ref": [
"r4"
]
},
"us-gaap_CashAndCashEquivalentsAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CashAndCashEquivalentsAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details"
],
"lang": {
"en-us": {
"role": {
"label": "Cash and Cash Equivalents [Axis]",
"documentation": "Information by type of cash and cash equivalent balance."
}
}
},
"auth_ref": [
"r104"
]
},
"us-gaap_ConcentrationRiskBenchmarkDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ConcentrationRiskBenchmarkDomain",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Concentration Risk Benchmark [Domain]",
"documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
}
}
},
"auth_ref": [
"r26",
"r28",
"r40",
"r41",
"r171",
"r421"
]
},
"us-gaap_DebtWeightedAverageInterestRate": {
"xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DebtWeightedAverageInterestRate",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_DebtWeightedAverageInterestRate",
"terseLabel": "Debt, Weighted Average Interest Rate",
"documentation": "Weighted average interest rate of debt outstanding."
}
}
},
"auth_ref": []
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual",
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-stock-option-activity-details"
],
"lang": {
"en-us": {
"role": {
"label": "Granted, shares (in shares)",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",
"documentation": "Gross number of share options (or share units) granted during the period."
}
}
},
"auth_ref": [
"r249"
]
},
"us-gaap_CommitmentsAndContingencies": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CommitmentsAndContingencies",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies (Note 7)",
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
}
}
},
"auth_ref": [
"r18",
"r47",
"r337",
"r378"
]
},
"us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
"documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
}
}
},
"auth_ref": [
"r37"
]
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ProceedsFromIssuanceOfCommonStock",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Proceeds from issuance of stock, net of tax withholding",
"documentation": "The cash inflow from the additional capital contribution to the entity."
}
}
},
"auth_ref": [
"r3"
]
},
"us-gaap_ConcentrationRiskByBenchmarkAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ConcentrationRiskByBenchmarkAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers",
"http://www.psychemedics.com/20230930/role/statement-note-11-significant-customers-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Concentration Risk Benchmark [Axis]",
"documentation": "Information by benchmark of concentration risk."
}
}
},
"auth_ref": [
"r26",
"r28",
"r40",
"r41",
"r171",
"r362",
"r421"
]
},
"us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
}
}
},
"auth_ref": []
},
"srt_LitigationCaseAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2023",
"localname": "LitigationCaseAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies",
"http://www.psychemedics.com/20230930/role/statement-note-7-commitments-and-contingencies-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Litigation Case [Axis]"
}
}
},
"auth_ref": []
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
"documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
}
}
},
"auth_ref": [
"r439"
]
},
"us-gaap_TradeAndOtherAccountsReceivablePolicy": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "TradeAndOtherAccountsReceivablePolicy",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-significant-accounting-policies-policies"
],
"lang": {
"en-us": {
"role": {
"label": "Accounts Receivable [Policy Text Block]",
"documentation": "Disclosure of accounting policy for accounts receivable."
}
}
},
"auth_ref": [
"r92",
"r93",
"r94",
"r174",
"r175",
"r177"
]
},
"us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-4-stockbased-compensation-tables"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
"documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
}
}
},
"auth_ref": [
"r38"
]
},
"us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OtherNonoperatingIncomeExpenseAbstract",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Other income (expense):"
}
}
},
"auth_ref": []
},
"dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityCurrentReportingStatus",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": []
},
"dei_EntityShellCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityShellCompany",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
}
}
},
"auth_ref": [
"r454"
]
},
"us-gaap_PropertyPlantAndEquipmentGross": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PropertyPlantAndEquipmentGross",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Fixed assets, net of accumulated amortization and depreciation of $23,312 at September 30, 2023, and $21,964 at December 31, 2022",
"documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
}
}
},
"auth_ref": [
"r75",
"r105",
"r345"
]
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "OtherNonoperatingIncomeExpense",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "Other",
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
}
}
},
"auth_ref": [
"r67"
]
},
"us-gaap_AssetsCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AssetsCurrent",
"crdr": "debit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 0.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_AssetsCurrent",
"totalLabel": "Total Current Assets",
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
}
}
},
"auth_ref": [
"r102",
"r113",
"r127",
"r178",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r295",
"r297",
"r310",
"r441",
"r485",
"r486",
"r520"
]
},
"us-gaap_PaymentsOfDividendsCommonStock": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PaymentsOfDividendsCommonStock",
"crdr": "credit",
"calculation": {
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_PaymentsOfDividendsCommonStock",
"negatedLabel": "Cash dividends paid",
"documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
}
}
},
"auth_ref": [
"r24"
]
},
"us-gaap_CreditFacilityAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023",
"localname": "CreditFacilityAxis",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-note-9-debt",
"http://www.psychemedics.com/20230930/role/statement-note-9-debt-details-textual"
],
"lang": {
"en-us": {
"role": {
"label": "Credit Facility [Axis]",
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
}
}
},
"auth_ref": []
},
"dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "EntityFilerCategory",
"presentation": [
"http://www.psychemedics.com/20230930/role/statement-document-and-entity-information"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Filer Category",
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": [
"r454"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "25",
"Paragraph": "1",
"SubTopic": "20",
"Topic": "940",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
},
"r1": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"SubTopic": "230",
"Topic": "830",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
},
"r2": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "10A",
"SubTopic": "10",
"Topic": "220",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
},
"r3": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "14",
"Subparagraph": "(a)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
},
"r4": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Subparagraph": "(a)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
},
"r5": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Subparagraph": "(b)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
},
"r6": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"SubTopic": "10",
"Topic": "470",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
},
"r7": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1A",
"Subparagraph": "(c),(3)",
"SubTopic": "10",
"Topic": "810",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
},
"r8": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"SubTopic": "10",
"Topic": "505",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
},
"r9": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)",
"SubTopic": "10",
"Topic": "718",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r10": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)",
"SubTopic": "10",
"Topic": "718",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r11": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(22))",
"SubTopic": "10",
"Topic": "210",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r12": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.19(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r13": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r14": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.19-26)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r15": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.20)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r16": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.21)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r17": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.22)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r18": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.25)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r19": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.29)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r20": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.29-31)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r21": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "210",
"SubTopic": "10",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02.30)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r22": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "220",
"SubTopic": "10",
"Section": "45",
"Paragraph": "14",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
},
"r23": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "220",
"SubTopic": "10",
"Section": "45",
"Paragraph": "14A",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
},
"r24": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "45",
"Paragraph": "15",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
},
"r25": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "45",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
},
"r26": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "275",
"SubTopic": "10",
"Section": "50",
"Paragraph": "18",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
},
"r27": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "275",
"SubTopic": "10",
"Section": "50",
"Paragraph": "18",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
},
"r28": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "275",
"SubTopic": "10",
"Section": "50",
"Paragraph": "20",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
},
"r29": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "360",
"SubTopic": "10",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
},
"r30": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "470",
"SubTopic": "10",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
},
"r31": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "505",
"SubTopic": "10",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
},
"r32": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "505",
"SubTopic": "10",
"Section": "50",
"Paragraph": "8",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
},
"r33": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "505",
"SubTopic": "30",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
},
"r34": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "505",
"SubTopic": "30",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
},
"r35": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "718",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r36": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "718",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r37": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "718",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r38": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "718",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r39": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "820",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
},
"r40": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "825",
"SubTopic": "10",
"Section": "50",
"Paragraph": "20",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
},
"r41": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "825",
"SubTopic": "10",
"Section": "50",
"Paragraph": "21",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
},
"r42": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "835",
"SubTopic": "30",
"Section": "45",
"Paragraph": "1A",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
},
"r43": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "835",
"SubTopic": "30",
"Section": "45",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
},
"r44": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "835",
"SubTopic": "30",
"Section": "45",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
},
"r45": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "835",
"SubTopic": "30",
"Section": "55",
"Paragraph": "8",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
},
"r46": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "942",
"SubTopic": "210",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03.10)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
},
"r47": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "942",
"SubTopic": "210",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03.17)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
},
"r48": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "942",
"SubTopic": "470",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
},
"r49": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "985",
"SubTopic": "20",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
},
"r50": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "205",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//205/tableOfContent"
},
"r51": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r52": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(20))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r53": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r54": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(29))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r55": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r56": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r57": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r58": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(31))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r59": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(32))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r60": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "11",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
},
"r61": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(10))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r62": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(20))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r63": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03.1,2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r64": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r65": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03.4)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r66": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03.7)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r67": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03.9)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r68": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "13",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
},
"r69": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
},
"r70": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
},
"r71": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
},
"r72": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "235",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//235/tableOfContent"
},
"r73": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "275",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//275/tableOfContent"
},
"r74": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SAB Topic 4.E)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
},
"r75": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "360",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
},
"r76": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "440",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//440/tableOfContent"
},
"r77": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "470",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//470/tableOfContent"
},
"r78": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
},
"r79": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
},
"r80": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.3-04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
},
"r81": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "718",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Section": "50",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r82": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.7)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
},
"r83": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "810",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//810/tableOfContent"
},
"r84": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
},
"r85": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(11))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
},
"r86": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(13))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
},
"r87": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(16))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
},
"r88": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(23))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
},
"r89": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04(15))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
},
"r90": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04(22))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
},
"r91": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04.9)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
},
"r92": {
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11B",
"Subparagraph": "(b)",
"SubTopic": "10",
"Topic": "310",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
},
"r93": {
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "15",
"Subparagraph": "(d)",
"SubTopic": "10",
"Topic": "310",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
},
"r94": {
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"SubTopic": "10",
"Topic": "310",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
},
"r95": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "2",
"Subparagraph": "(a)",
"SubTopic": "20",
"Topic": "740",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
},
"r96": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"SubTopic": "210",
"Topic": "946",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
},
"r97": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "9",
"Subparagraph": "(b)",
"SubTopic": "10",
"Topic": "740",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
},
"r98": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h))",
"SubTopic": "10",
"Topic": "235",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
},
"r99": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Topic": "606",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//606/tableOfContent"
},
"r100": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "105",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
},
"r101": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "205",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
},
"r102": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
},
"r103": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
},
"r104": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r105": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(13))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r106": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(14))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r107": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(17))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r108": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(18))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r109": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(20))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r110": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(22))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r111": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r112": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r113": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r114": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1A",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
},
"r115": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
},
"r116": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
},
"r117": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
},
"r118": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
},
"r119": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(210.5-03(11))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r120": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(25))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
},
"r121": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "17",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
},
"r122": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
},
"r123": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
},
"r124": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
},
"r125": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "8",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
},
"r126": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(c))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
},
"r127": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
},
"r128": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
},
"r129": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.12-04(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
},
"r130": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "23",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
},
"r131": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
},
"r132": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
},
"r133": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
},
"r134": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
},
"r135": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
},
"r136": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
},
"r137": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
},
"r138": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
},
"r139": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
},
"r140": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
},
"r141": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "8",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
},
"r142": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "9",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
},
"r143": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//260/tableOfContent"
},
"r144": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
},
"r145": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "16",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
},
"r146": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
},
"r147": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "60B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
},
"r148": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "60B",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
},
"r149": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "7",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
},
"r150": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
},
"r151": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
},
"r152": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
},
"r153": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
},
"r154": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "15",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
},
"r155": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "272",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
},
"r156": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
},
"r157": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
},
"r158": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
},
"r159": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
},
"r160": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
},
"r161": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
},
"r162": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
},
"r163": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
},
"r164": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
},
"r165": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
},
"r166": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
},
"r167": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
},
"r168": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
},
"r169": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "40",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
},
"r170": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "41",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
},
"r171": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "42",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
},
"r172": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
},
"r173": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "9",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
},
"r174": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
},
"r175": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
},
"r176": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
},
"r177": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
},
"r178": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "323",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
},
"r179": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "4",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
},
"r180": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "5",
"Subparagraph": "(c)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
},
"r181": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
},
"r182": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "440",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
},
"r183": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "440",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
},
"r184": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "450",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
},
"r185": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
},
"r186": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
},
"r187": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
},
"r188": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
},
"r189": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
},
"r190": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
},
"r191": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
},
"r192": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
},
"r193": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
},
"r194": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r195": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r196": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r197": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r198": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r199": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r200": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(g)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r201": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r202": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r203": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1C",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
},
"r204": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1C",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
},
"r205": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1C",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
},
"r206": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1D",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
},
"r207": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1D",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
},
"r208": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1D",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
},
"r209": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1E",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
},
"r210": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1E",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
},
"r211": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1E",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
},
"r212": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1E",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
},
"r213": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1F",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
},
"r214": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1F",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
},
"r215": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1F",
"Subparagraph": "(b)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
},
"r216": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1F",
"Subparagraph": "(b)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
},
"r217": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1I",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
},
"r218": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1I",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
},
"r219": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1I",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
},
"r220": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(b)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
},
"r221": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
},
"r222": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.3-04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
},
"r223": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
},
"r224": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
},
"r225": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
},
"r226": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
},
"r227": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
},
"r228": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
},
"r229": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Subparagraph": "(b)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
},
"r230": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "15",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
},
"r231": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
},
"r232": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
},
"r233": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "9",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
},
"r234": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r235": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r236": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r237": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(B)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r238": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(C)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r239": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r240": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//718/tableOfContent"
},
"r241": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r242": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r243": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r244": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r245": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r246": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r247": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r248": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r249": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r250": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r251": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r252": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r253": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r254": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r255": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r256": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r257": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r258": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r259": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r260": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r261": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r262": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r263": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r264": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r265": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r266": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r267": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(v)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r268": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r269": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r270": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r271": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r272": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(l)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r273": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "15",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
},
"r274": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "15",
"Subparagraph": "(f)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
},
"r275": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "15",
"Subparagraph": "(f)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
},
"r276": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 14.F)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
},
"r277": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "730",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
},
"r278": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//740/tableOfContent"
},
"r279": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
},
"r280": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
},
"r281": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
},
"r282": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "14",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
},
"r283": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "17",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
},
"r284": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
},
"r285": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "21",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
},
"r286": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "8",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
},
"r287": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "8",
"Subparagraph": "(d)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
},
"r288": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
},
"r289": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
},
"r290": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.Fact.1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
},
"r291": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.Fact.2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
},
"r292": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SAB Topic 11.C)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
},
"r293": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "270",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
},
"r294": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
},
"r295": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
},
"r296": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
},
"r297": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
},
"r298": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
},
"r299": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
},
"r300": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
},
"r301": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
},
"r302": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
},
"r303": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
},
"r304": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(i)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
},
"r305": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(e)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
},
"r306": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(e)(4)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
},
"r307": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
},
"r308": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
},
"r309": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
},
"r310": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "825",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "28",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
},
"r311": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "17",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
},
"r312": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
},
"r313": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
},
"r314": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
},
"r315": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
},
"r316": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
},
"r317": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "835",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
},
"r318": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "835",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
},
"r319": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//842-20/tableOfContent"
},
"r320": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
},
"r321": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
},
"r322": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
},
"r323": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(g)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
},
"r324": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(g)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
},
"r325": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(g)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
},
"r326": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(g)(4)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
},
"r327": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
},
"r328": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "848",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(a)(3)(iii)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
},
"r329": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
},
"r330": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
},
"r331": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
},
"r332": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "924",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 11.L)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
},
"r333": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04(27))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
},
"r334": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
},
"r335": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r336": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r337": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r338": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r339": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(21))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r340": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(22))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r341": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r342": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r343": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r344": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r345": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r346": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(11))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
},
"r347": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(18))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
},
"r348": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
},
"r349": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
},
"r350": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column A))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
},
"r351": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column B))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
},
"r352": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column C))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
},
"r353": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column D))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
},
"r354": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column E))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
},
"r355": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column F))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
},
"r356": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
},
"r357": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(f)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
},
"r358": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(f)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
},
"r359": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(g)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
},
"r360": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(g)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
},
"r361": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(h)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
},
"r362": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "825",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
},
"r363": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
},
"r364": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
},
"r365": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-03(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
},
"r366": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
},
"r367": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
},
"r368": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
},
"r369": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "21",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
},
"r370": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
},
"r371": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r372": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r373": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r374": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r375": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r376": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r377": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r378": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(15))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r379": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r380": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r381": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r382": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r383": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r384": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r385": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r386": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r387": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r388": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r389": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r390": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r391": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r392": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r393": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r394": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r395": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r396": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
},
"r397": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
},
"r398": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
},
"r399": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "3",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
},
"r400": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "7",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
},
"r401": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r402": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r403": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r404": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r405": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r406": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r407": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r408": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(6))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r409": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r410": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r411": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r412": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r413": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r414": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(6))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r415": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r416": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
},
"r417": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(1)(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
},
"r418": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
},
"r419": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(6))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
},
"r420": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
},
"r421": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "954",
"SubTopic": "310",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
},
"r422": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "954",
"SubTopic": "440",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
},
"r423": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "13H",
"Subparagraph": "(a)",
"SubTopic": "40",
"Topic": "944",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
},
"r424": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
},
"r425": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "52",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
},
"r426": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
},
"r427": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "31",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
},
"r428": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
},
"r429": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "69B",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
},
"r430": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "69C",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
},
"r431": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "69E",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
},
"r432": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "69F",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
},
"r433": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "91",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
},
"r434": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "91",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
},
"r435": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r436": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r437": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "17",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
},
"r438": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r439": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r440": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "53",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
},
"r441": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "852",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
},
"r442": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
},
"r443": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
},
"r444": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
},
"r445": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
},
"r446": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "310",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
},
"r447": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
},
"r448": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
},
"r449": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
},
"r450": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
},
"r451": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "830",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
},
"r452": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "830",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "12",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
},
"r453": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r454": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r455": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r456": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "240",
"Section": "308",
"Subsection": "a"
},
"r457": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Section": "13",
"Subsection": "a-1"
},
"r458": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "405"
},
"r459": {
"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
"Topic": "450",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
},
"r460": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "18",
"SubTopic": "10",
"Topic": "275",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
},
"r461": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1B",
"SubTopic": "825",
"Topic": "944",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
},
"r462": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(g)(1)",
"SubTopic": "20",
"Topic": "842",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
},
"r463": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4H",
"SubTopic": "40",
"Topic": "944",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
},
"r464": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r465": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(3)(a)(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r466": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
},
"r467": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
},
"r468": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
},
"r469": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
},
"r470": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
},
"r471": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
},
"r472": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(f))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
},
"r473": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
},
"r474": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
},
"r475": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.12-04(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
},
"r476": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "23",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
},
"r477": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
},
"r478": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
},
"r479": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
},
"r480": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "13",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
},
"r481": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "323",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
},
"r482": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "450",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//450/tableOfContent"
},
"r483": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "450",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "9",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
},
"r484": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "450",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
},
"r485": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
},
"r486": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
},
"r487": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "606",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
},
"r488": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
},
"r489": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r490": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r491": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r492": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r493": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r494": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r495": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r496": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r497": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r498": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r499": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r500": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r501": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r502": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r503": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r504": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r505": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r506": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r507": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r508": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r509": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r510": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r511": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r512": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r513": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r514": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(v)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
},
"r515": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(e)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
},
"r516": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "825",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "28",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
},
"r517": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
},
"r518": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
},
"r519": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "850",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
},
"r520": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "852",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
},
"r521": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "852",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
},
"r522": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "912",
"SubTopic": "730",
"Name": "Accounting Standards Codification",
"Section": "25",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
},
"r523": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
},
"r524": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
},
"r525": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "13H",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
},
"r526": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
},
"r527": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "3",
"Subparagraph": "(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
},
"r528": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
},
"r529": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
}
}
}
ZIP
58
0001171843-23-007042-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001171843-23-007042-xbrl.zip
M4$L#!!0 ( **;5<&B+O@I@< "XM - 97A?-3DP.3@R+FAT;>U:
M;6_;-A#^W/P*PD.[!K ;.VG1+G8,N)G;!NN2+'&![2,E41%12E1)RH[WZ_<<
M);_4+VG2.FY7Y$L<\>7N2-YS]QRE3N)2U>TD@D?=G4<=)YT2W7>#/]^S?B2=
M-IV]L@E]J7""J.:K$V*7>-2#@1.JFS&@MUYD2&
MT4XHD29KG5W.GNEPDZ@HS&S;JS\],PU8IY*-3YD3SX5VK4',A66G8H1
MN] IS\K&.O/-=6:%D7&;^7E6_BL.6:N9NS;+>13)[.J0-67&FL]:,FNSL#!6
MFT/&"Z?;9$%^5[4K%/F&(3>29^Z09;1\U68I-UWEW9XT%OR[H_K4]T^J5?J:S4EEI+!4^R0*;MV_2L?%5,B>N78,K
M>86&$ N(/F
M_H]CU-D;-GC79Y>]B]>]T_YEX^SO]_U_6.]XP-"SW_RRJ=MPHV_7<5)GKZF7
MO2N4 F*%J6,;C)/QF+F$N\,M+M'Q0 EH5ZH*'T7]%
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M0,@3F,$U'6"8."-L3C%=OR,_BAP\PO@\8'_P(,!8LEAG@04B;P:$.
MY&(XNLUMFV%2JKDH<2E(YCB4?O\">,&^&A!:A(JDX 28L
M52K2)C2PI(10(8+7'3OPX3
MCLJ+]9 1+PJ%$:T#3@8V?VNW7CP5NUY ZT4TWU8V2BI8LQ+GI2[*H7/X+U%(
MALUK189=K;4!V?%47_FTZQ>]&!4P@AC\X8*#[N"7RKA[KQD?*L?O43G>% :W
M5ZCRW9L*U><;76\D+#0#,Y[B?AG==6+?(2_L[:<0#0X$FVHJB;4NX"$%,NU0
M6I^_,4ID7@Y=S,PR_SR/,$)QC_:*6<\06Z\X!G5*L #88K62$7?>T,#*2 )T
MM !9\G_/;#*25%B*Y26D_@?;;75L @!W9!DW).)U4H3KD?R_)&S+@]9I25
M@F<)58_P)! \$C,%]$/TNZVR9;6)]=@Y4PV7AV??YX"2:+:6EM5EI"RZUG
MWAXT -I01H0%;G7F,P6WP!%5L000;J*)LP(^D@=223-B&3:Y/P4<
M,!%QWY;%7J +M]Z"VV0W/ATMJ*:-;[K J:P()M6R1WBU$["G3<(?/'J#'AUM
M,^*7SK+L='1+6=46OF>E9]\ASA/9T6%8&'*M.6:Q0FJJK4,[O<>#+(O]F5Q(
ME&(2;J>\B8*M!X&(?!;R"Z@RQ)@I^5&HZGIT87S]F]>T&,:W5C0]E$NW*Y=6
MH6N#-<6++;YH^[IK#_]R;HKP^BR$4T:91]DLFE,NN /O6RI0IJ;QPG_V8J=4
MRS= 9)I*YX2X(5\&&F2.^B,)^TC(=[N?>(#:3WTSL=U+"+KIISI' J-T^T;W
M>*$4 %7% *>7 2/!/Q*E*^L,3^I\A>3?"4YN_>\$U:IN+R]"5^1''F&B%=/T
MN!;655V%*< FRI]ZR2LM+;Q(X8]8L5],Q2-6OBEYX(S?H&Z;%P+$ F.#T%V'
M PF?;>""_F5PY:OUDI/);*C54! QR_A5]4[;5 E*I+G28X'>4:++K,0_0P(\
M=R,T\]D/D2<"P$(8)(3:0LI83!CWFRYFF6!=)/7N]#L.\G#^-G[^+SO%5J.\I\6EWOP!O%5'#%QG:_LU=&<4/K-BC3Y1QT/X[Z?\ 4$L#!!0 ( **;5=:X!,%; 0 *H6
M - 97A?-3DP.3@T+FAT;>V8;4_C.!#'7\.G&/6TNR U?5SNH"F12@D/
M.K;MMD&Z>^DF#K'DV,%Q@.ZGOW&24AH6#FXY%MTA4:*,)S-_CYV?[?0C'7.G
M'U$2.)L;?9E+;'HMI"B-Z#5,9$U$8ZY";ZY!2Q4(;\N=2]HWVH-U*M T)"0(F
M+GK08@):C383-OB92J7J *PN/UX)'SM/5='SH3OU3H].AP/O=#R"R?ET
M=CX8>>"-X>_J\'H:SQNSQK !,W>8BVQW=UIO1]Q@!H/#\<1S#]]H]99EVVO]
M"N,C\$Y0N3_\=SG-;AP+3"2<8YDHFJ
M.@PC1D-P;ZB?:79%81R&S*<*B A@HFC*#!) AC!)%WY$8QHP/X6A5(E4Q- 5
MMG1$X>,ONYU.RQ[*."%BD=^U[>TZ5EQI%B[JD"#X,A0&6D)[%Y9SMR!T/G?K
M0%(@@4PT#=;13CDB@F?)80#O2V
M<[+L7!FE5%O'&Z)[KSB^FLPYQ=IP7JX1^S7TJN66-"'^RE)JN6:!CLRD;WTH
M)_U+K!2%0,NL .7+4EH4NXANUX'-C%%U#<&04((F13/,?[
M+M*JT^IT<]J$C&/C-=-1P2:DC6*:86<,1-T;W*LB:XV"F*6I(1G^C>15$:K=
M+4*M<;30M,)HB,!>X#8V3KB)>YM+TZGVVCMSI;\*H, O!JH/5.R'="_L<(V7DG9$Y()HJ#L^&'.3 3
M)A!K>'0UZ"@A&1)FD)G@QM @IVZ:"><8#2G)<*^%#0DR**WG3X5,$-R$H1T#
MXCG>A#9,1*^,%\22"2WVD6EE5]9X4R2:2Q50AC5_2B^']_N7GXK5^+A >E?N8TTV;UY%#&O9NDW\R_0_[E' KL#G)$WW:V>#F6=-!L>N=3!U![^;;Z=W6B?'1]ZT8HM"2\GK^T8#
M;)@'-D[5W=<^(X$G^_JOL?=+S=?'Z<^NB="4LY.6]V#3@L1YG*/LO%IZ^>=T[OK7URTD%28>=CG
MC)RV&&_]^N7O?_O\#\?Y3A@16!$/#9_08!(PCXBO?$K0[V>WE\A!G5].CKHW
M5^CGH(\..X='3K?K=(\P(/3UD2IV4F[_?#P!P
M=,#%N'W8Z73;OU]=WAG:5D3L\H I\914>!P*_T 2]V#,[]M185LS3"H$0H!>
M136BTDP5C]!\:BC($BKAJ*<9D1GY316M 12W=;&NTW$Z7>>P&]M77Q$$L2DS-,79G?M"G*M#V;9FTTDT_:+,0#
MP@.73PUQY_BH$U>0U,UO&PHR+4NA$L(1ED,C,#Q<)%KHZ#1I6)2MH&:B@#^4
M9$@#Z8PQGCUO.2I8)"Z0(R[)D&O.GLH*$AGD0SLL3)/2)>:C3(]$-S'?XS-S
M1^.F>WQ\W#:E+825$G08*/*-B^E7,L*!#]($[*\ ^W1$B0=CW@[I*?+.&!"E_4HE]0F^N
MUF \]ZJ5^,;D^F(UKCGN92G'9_1MXBMI/$Y];>?^KY*V,;F^J*GM@F>JIG+:
M^85JQ\W4T/V9RZLXP.,*>F1_J-G=G-5'U\UNOPYRFKT=\'LM8;1
M]9/59"@/@HK$*:MI[F5-#YL-]:JYV'2=Y&X=)YN$=]5\;$2N+]:P 0R?X[;@
M/FDS,M9!>[41Z N1J:6'X;&>8+L?%^7 C'%EFC+/XJ>S&64C'CV"ASHJ.8D#
MT5LR0B9..<'"U7R61S/MF> S(A2%896*94T#$T%&IRT(4ITX!/G#Q\,#B)1B
MBF?M9P,)HR94(?[E7+JXK@;=:4M"7_LD4GK;VKC87U4;J.(&OK');NKDD=&J
M.D$5RNCNJC039%65H(J$^+N6G70# R! %%9G$ 0K$\H['G<#A6.C.B(7>]4.YT(V1"_V,Y?I7@Z9Z!G5F6#^?$$6A
M4^2+@FM1%EM8.[2,-?3N)B-H [Y%@R<$TN$C1\_'AKGKP-<6J(ZJ@2HA
MD8B/T'4B$7K7^*Z*9I03&&T3[GM$2(?\%>CP9:LX6BZ +4"]KP.HNY1H_T3G
M1K8&6G8LNY6I<0UY; 'OPR: U\R1JUG>Q7+BC'S^L.4Y,I>O+61]K(.L/DB$
MOFF)&D>FS$J7#N
ML1\09TJP[C/C VV8NKAQ6\8^SC6V7A1] \[H-\T97:4X[[FYW\.\RUW3?7H^
MGLY@'K0VLHL;MV3N;B?7W.&2!3@[AC7,ZG/6>V[O#^!BP1+$4?B16!G3"RW:
MLFPWU[)Z37!AV*&!9K?GUOQH8B37O$#QJ!_H.)H1Y4"G29W!=N-JQ8V=CQ(=8ATK%A]+QF;1GZ
M?:ZA=>A^'?-$EX;GGMOVV/'(4-DP9]22+0M^R+6@B<>!S9Y;K=MQ!+DG++ R
M&:=:LV6]C_G9$!U?WX:L]MV"74?2,:,CZF*=Q Q@:3,EPLIL6MBV+>L6Y+K,
M9H^OK=-VP*[9"Z^GNQGWJ0XLDHLUS5Z9C2T$/$N"I>W>2R1 -Q%C
M]"Z^VO<4=V'."A:\0]]..%W*PQ8,5DZ/H7<#(\&^HZ PE641!:4\+*'@6L
M60.#5=(@%C&Q&D-; ,E/OE5-OS1@*5POVP-&<>.V0)"?@\M;DC<&3Z^H+1HY
MVZ MP^8GU>*5>F/,Q46V18,^;]264?,3:.D%?&/8I?L-8*@I3'UPH^11!=C?
MX-:&9ZQL@2 _!U>XU0&]^QH*@@:A(/L.C>)U&):21&\Z?(J'U*?Z2ZZ8QG/
MJ!B&MOZ$0,_(X=:ER,R;72&N)9DMX.6G#Y>M*QW4,X*;6/)R+GA,Y2$0 8/O
MB@2/=F7%B-UWI!:O%3?@QJHSLX6G_(3E\A5JX\LJ&FWA1BJ;CJH.6UNHR=_I
MMQ0U3O:V#V(U/J;4E.8Y+$#-#785O==?!&P%1EJZ!U?(-C9N(?DHX
MV()'M0V/39A3+T&^ 5S4Y&P++^MMD6QP5,^:SXD>"!U/S/1Q3P0>$[,S4@[AQC>6OVO< $HJ<+$%C/P\>?ZKS08+95::8A6(
M,.O,1^'#3"K:XK2W!G=;V,E/=>=BQT%7B7#Z>V+S.)/L;B:ES(ON#7B5@I9M
MH2$_43U_E]YXCSQKZ!" JPF$J='[41C.6 @,,W 8(^A#1;W )WI(FQJ"S/!3
M6&;1G=@4QQ:B\I/8":)TM'*M98U?Z8*[Z:5DU>FD2%KME$P^$2VSB; 5NMF"4G\'.[ >97PV?8*8"8="=$:9!2M2#/H0>U3$@^.P>\_IX1A7VK\AT2$3+G+Q]VJI(2WU?[^6*
M.8/IF[3,V^_JL/+AC%E_A!!E1E-2LNWDEE)I2,SA^)"V+K743]\,N4,)@3QM*A\=*PN
M:$Z&5-FR:7QL-ZAW;@[MOD@?0Q5UPW*:^JJ"2-"#MF%ZSJ;X#H^Q5"#U;S>I
M<*'/Q8R'#68!O%J571R;^DS&F::XY)BE5BX+>I91[:)J%X!ZIB> &Q@ $&]]
MS.I47+P++@BD$SH_]96$OQ>LY[H@CG?^J#E&-O4GL5CZZU$23R59XT4-"VAV5C>SQ>-,[YE,;YE,A8IG3W.22$FSAS(\%/R"
M 9J#4'-MS,$$LW#K+D32[)X(1;P!#[>3F/V9%RS\PXVXWUZ0_QH.VNR+67?X
M&+V&Y:H/5U==(\/W=9"8T]M;8_F&.S@76_$VJF@7U?DC$2Z5Y$90_2>Z&[=
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M5K][*NDPN[Q>6Q=71-4B]6M0L_I_4Q0KOT(;6^N2\,L*#<&UL
MW5UM4^,X$OY^5?I8;?"RTRE"@@58'?OTY5BMXEN'"DGR8'<
MK[^6XX1 _"+;0193-340IR7WTU*_J+MMOOS^/(LZ"Q"2=H\.C8Z_?]_K'GO?;EXBR[Y_U?Q,B
MH8-,,)E\/.U.E9I_[O6>GIX.GB'C<6U-W4W+];: V [:)?^ZM
MOMR0[DS]=)S0]D].3GK)MQM22;,(<=)^[Z_KJSM_"C/B4:8EXFM>)/TLDXM7
MW")X_/]2+BBGL1X%VE-R,J
M%E11_)6'JXO($YG0:'4Q $5H)!%\PLM40'C:G<\";WTCS>T_]GX?M9SC]I-T
M-H^@V]L2AD\B/XX2X5_AYY1<@VU5+BM^X5D!ZD6Z>FN6(^Z_DIYF4ZYW<4CD
M)-D2L?0>"9DGC/8@4G)])9%T(N7TPK^O0$J T9KE*\W<5=D]C_!43+[P/HRBWM(Q^A6J':JH_ KE6CF-,=-0!=.6(1_R\0.A-_A N52BIZ,9[-D3H^BZ5V/#P6?-;!,?$\; 9DT
M$D+_!Q%"L;DSE<;1#R*-'#MH*H;C'T$,!M;B11Y?>EFQV+N$K"<8:4V4AT<2
MCZLI""^D#*-Q':D1(0A[3&BEI^/R((Y 1VO)" 'S%%J]&/8=;FPWJ'TW +:B
M7,X>[T',+I"G/#^806+7LV\Q<+TY,8PW AR%MX*BS.1&7TD,O[,DI
M$9!!M!(^_D(6Z*L?P<-;S5":";WT>*R2W)RVX+5<6@N,V75YK0&TY!+_3-D<
MK+B\B6<3$!1V$>MU40E\_B M(=
MYL[T)JZ&LW@.-]UDW27C>Y&&2Y[SO2115>-M^U2?HV5E$HTS_B9Y1 -=A4(C
M'NFJ#)IH #RI^+$0FAJM/.6!%S,2!RC+P-A#[N!,QYH%X^4:(?R>'[U90M\E>A %HU5+L^)G Y8
MH']<_C=&0Q+I(_! G1,AENBB_R!1;I6WTEB[J'!/TB2PD)I!SG16&O!,#WD;
MQ6"$=02I5A4N00Z955XO( 3CC4.KF2]>AB-8JU[Z]0->ITM
M818K H23U:=["F ^TBLUJ5O2[F?M,]/